



Opioid and Opioid Use Disorder: An Environmental Scan

July 12, 2019

This report is funded by the Department of Health and Human Services under contract HHSM-500-2017-00060I 75FCMC19F0002.

Contents

Introduction and Background 3

Methodology and Approach 5

 Domain 1: Pain Management..... 6

 Domain 2: Treatment of Opioid Use Disorders (OUD) 10

 Domain 3: Harm Reduction 13

 Domain 4: Social Issues 15

Next Steps 17

References 18

Appendix A: Committee Members, NQF Staff, and Federal Liaisons 24

Appendix B: Environmental Scan Strategy..... 28

Appendix C: Key Informant Interview Guide 33

Appendix D: Measure Inventory 35

Appendix E: Measure Concept Inventory 62

Introduction and Background

Data from the U.S. Centers for Disease Control and Prevention (CDC) show that overdose deaths involving prescription or illegal opioids have persistently and sharply increased since 1999.¹ The CDC considers these increases in opioid-related mortality to be an epidemic, and President Trump and many state governors have declared public health emergencies in response.^{2,3}

Since 1999 approximately 800,000 U.S. persons have died prematurely from drug or alcohol overdoses, and more than half of these deaths have involved opioids. This makes annual overdose deaths more lethal than U.S. fatalities related to guns, the Vietnam War, the HIV/AIDS epidemic, and automobile fatalities, underscoring the deadly impact of this epidemic.⁴⁻⁷ OUD is one several substance use disorders (SUDs) included in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) including alcohol, tobacco, and cannabis disorders. Many people, including those with OUD, have more than one SUD.⁸ Additionally, over 2.1 million persons suffer from opioid use disorder (OUD), a condition connected to frequent misuse of substances that include common pain medications and illegal drugs like heroin. If left untreated, OUD may yield substantial and premature disability and death.^{9,10}

OUD affects brain biology and typically produces serious social problems at home and work, memory and motivation issues, intensive and increasing drug cravings, poor self-control, and severe emotional problems.^{4,9,11-15} OUD is further correlated with an array of side-effects and comorbidities including persistent nausea and constipation, tremors, seizures, increasing pain, and infectious diseases like hepatitis C and HIV/AIDS (both correlated to unsafe drug injection and sexual practices).¹⁶

Prescription opioids are also well-established analgesic agents and are widely used to address acute and chronic pain, often with complementary therapies through integrative approaches. Accordingly, responses to OUD are expected to include strategies that optimize the treatment of pain as well as the treatment and prevention of OUD.^{4,17} In fact, the opioid epidemic is now typically characterized as iatrogenic in its origins—stemming in part from the American Pain Society’s 1996 call for pain as the “fifth vital sign,” and from a 2011 National Academy of Medicine (NAM) report which labeled pain as “a public health crisis.”^{4,18}

Maintaining the balance between pain management and opioid misuse reduction is especially complex and consequential because more than 100 million Americans are estimated to suffer from chronic pain, and 10 percent of those individuals take opioids as a part of what is presumed to be a multidisciplinary and patient-centered approach to care.¹⁹ Accordingly, one concerted response to the opioid epidemic has been to advocate for better pain management practices that help curtail unnecessary opioid use via nonopioid therapies—without forcing those who benefit from opioids away from regimens that spare them substantial and needless suffering.¹⁸ HHS has developed a National Pain Strategy, and in 2019, its Pain Management Best Practices Inter-Agency Task Force issued a comprehensive Final Report on updates, gaps, inconsistencies, and recommendations for the treatment of pain in America, as required by the Comprehensive Addiction and Recovery Act of 2016.²⁰ The report notes that “classes of medications, including non-opioids and opioids, should be considered for use. The choice of medication should be based on the pain diagnosis, the mechanisms of pain, and related co-morbidities following a thorough history, physical exam, other relevant diagnostic procedures and a risk-benefit assessment

that demonstrates that the benefits of a medication outweigh the risks. The goal is to limit adverse outcomes while ensuring that patients have access to medication-based treatment that can enable a better QOL and function.”

Solutions to the opioid epidemic must thus remain mindful of pain as an important treatment target, but also focus on prevention, treatment, harm reduction, and social determinant issues that influence a person’s risk for OUD and overdose.^{17,21–23} Harm reduction and addressing social determinants are especially important but often overlooked responses to the opioid crisis. Harm reduction approaches typically refer to acute pharmaceutical remedies to overdose but may also include strategies such as heroin contamination test kits, needle exchange programs, and overdose prevention sites.^{21,24,25} These latter three approaches are controversial. Although they mitigate the dire risks of near-term morbidity and mortality from overdose or infection and they also provide gateways into treatment and recovery, some believe that such strategies also encourage illicit drug use. Naloxone use is also controversial, but far less so because of its exceptional ability to rapidly reverse an opioid overdose. As of late 2017 nearly all states had laws or specific policies in place expanding the use of naloxone as a safeguard against opioid overdose.²⁶ Though many harm reduction policies remain controversial, their expanded use or consideration by health professionals underscores the urgent challenges posed by the opioid epidemic in the United States.

Social determinants also are important to consider when addressing the opioid epidemic. These include economic and cultural factors that influence one’s risk for OUD or alter one’s access and response to proper OUD treatments. Recent reviews have found that opioid-related mortality is linked to specific race, age, geographic, and financial stress factors. For example, analyses of data from 1990-2013 revealed that non-Hispanic white, middle-age, non-college educated males with low socioeconomic status have increased risk for opioid-related deaths. This is even as rates for women increased more rapidly, and black urban dwelling Americans were at greater risk for such deaths in the early part of this period.²⁷

Additionally, recent public health and economic trend analyses have concluded that while supplies of prescription and illicit substances have contributed to the opioid crisis, it is now “...fundamentally fueled by economic and social upheaval...” which can push individuals toward “...opioids as a refuge from physical and psychological trauma, concentrated disadvantage, isolation, and hopelessness.”^{28,29} With regard to cultural factors, stigmatizing forces—stereotypes that create social distance between those directly impacted—are especially strong for OUD versus other conditions including psychiatric disorders, and thus stigma is arguably of unique relevance to the OUD treatment and prevention enterprise.^{30,31}

Federal and regional responses have been cast widely in recent years to address the opioid overdose epidemic. Physicians have altered their pain management approaches; state governors and other leaders have instituted surveillance, public health, and healthcare financing remedies; and the public at large has attempted to diminish its overall use of opioids. Rates of overdose deaths may, in some regions, be slowly receding although they remain at high levels.³² At the federal level, recent laws that directly target the opioid epidemic include the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act signed by President Trump in October of 2018.

The SUPPORT Act contains provisions to expand treatment options, the largest being permission for state Medicaid programs to receive federal reimbursement for substance use disorder (SUD) treatments delivered in institutes for mental disorders (state mental hospitals), a special exception for Medicaid reimbursement that could infuse one billion federal dollars into state SUD treatment efforts over two years.^{33,34} Other federal proposals currently under consideration include treatment system expansions of \$100 billion over the next 10 years. Such expenditures are justified by analyses that show the opioid crisis costs the U.S. economy hundreds of billions of dollars per year in treatment, incarceration, and lost productivity and life-years.³⁵⁻³⁷

The SUPPORT Act also calls for the establishment of a “technical expert panel for the purpose of reviewing quality measures relating to opioids and opioid use disorders including care, prevention, diagnosis, health outcomes and treatment furnished to individuals with opioid use disorders.” Under the authority of this law, the Department of Health and Human Services (HHS) contracted with the National Quality Forum (NQF) to establish a multistakeholder technical expert panel (TEP) ([Appendix A](#)) to consider opioid and OUD-related quality measures, including an inventory of existing measures, measure concepts (i.e., measures that have not been fully specified and tested), and apparent gaps. The National Quality Forum (NQF) is an experienced convener of multistakeholder groups for developing consensus around diverse and challenging healthcare quality topics. This report summarizes the findings of the environmental scan which is based on a review of existing quality measure databases, recent literature including technical reports, state laws and policies, peer-reviewed publications, and key informant interviews.

The TEP will use this scan of opioid and OUD-related quality measures to craft specific measurement recommendations to HHS for the purposes of improving management, prevention, diagnosis, and treatment of persons using or misusing opioids. The TEP will then provide recommendations for revision of existing measures and possible development of new measures to address existing gaps. In addition, the TEP will develop a list of recommendations for inclusion of measures in various federal healthcare accountability programs such as the Merit-Based Incentive Payment System (MIPS), alternative payment models (APMs), the Medicare Shared Savings Program (MSSP), the Hospital Inpatient Quality Reporting Program (IQR) and the Hospital Value-Based Purchasing Program (VBP).

Methodology and Approach

To inform the TEP’s work, NQF conducted an environmental scan to help assess the current state of opioid-related healthcare quality measures, using a search strategy with inclusion and exclusion criteria. The primary goal of the environmental scan was to assess the current landscape of quality and performance measures and measure concepts that could be used to assess opioid use and abuse. For the purposes of the scan, the following questions guided research efforts and ensured that the information sources collected are relevant to the project objectives:

- What current or emerging quality of care measurements (i.e., metrics, indicators) exist regarding the use of opioids for pain management or the treatment and prevention of opioid-related abuse, dependence, and death?

- What are the major current and emerging concepts (i.e., facts and science-based theories) regarding opioid use and misuse which can be used to evolve associated quality measurement?
- What directions should quality measurement science take to advance the battle against the U.S. opioid overdose epidemic, i.e., where are the apparent and important gaps?

Information was synthesized from peer-reviewed, scientific literature, grey scientific literature, quality measurement databases, state laws responding to the opioid crisis, and key informant interviews. [Appendix B](#) offers more information on the methodology of the environmental scan, and [Appendix C](#) presents the key informant interview guide.

Environmental Scan Summary

The environmental scan focused on measures where specifications were available and resulted in a total of 206 measures ([Appendix D](#)) and 80 measure concepts ([Appendix E](#)). In addition, the TEP and key informants identified multiple screening tools, scales, and other instruments for measuring pain, OUD, depression, psychiatric disorders, tobacco, alcohol use, and other conditions associated with opioids and OUD, but not specified as quality measures or concepts. Some items were excluded from the scan if a comparable performance measure or measure concept was already identified. The environmental scan with guiding input from the TEP and key informants yielded four main categories (domains) of measures:

- Pain management
- Treatment of opioid use disorders (OUD)
- Harm reduction
- Social issues

Measures and measure concepts were then further divided into smaller groupings within each domain (subdomains) as described below. These domains and subdomains are meant to organize the measures in a way that facilitates the identification of measure gap areas. Measure ideas—measures that do not yet have a numerator and denominator—identified in the search either directly or as a gap are also discussed.

Domain 1: Pain Management

Within the pain management domain, there were a total of 124 measures found, complemented by an additional 44 measure concepts as noted in Table 1. The measures selected for this domain were designed to assess how effectively providers address pain. The emphasis is on physical pain related to things like postsurgical care, inflammatory conditions, and physical trauma. The relevance of this issue is underscored by the very high prevalence of opioid prescribing that addresses pain. Approximately 100 million Americans per year receive at least one opioid prescription to address acute or chronic pain.^{16,19} These measures and measure concepts were divided into the following subdomains: pain assessment, pain score change, time to pain management, quality of life (QOL) and function, pain care plan, non-opioid pain management, and appropriate opioid analgesic prescribing.

Table 1. Measures and Measure Concepts for the Pain Management Domain


Subdomains	Measures	Measure Concepts
Pain Assessment	21	4
Pain Score Change	21	0
Time to Pain Management	4	1
Quality of Life and Function	13	1
Pain Care Plan	10	1
Non-opioid Pain Management	9	1
Appropriate Opioid Analgesic Prescribing	46	36
Total	124	44

Overarching Themes

Pain management has consistently been a critical issue at the heart of the opioid crisis. Figure 1 depicts how the first wave of overdose deaths (from 1999-2010) coincided with the use of prescription opioids, which include drugs that in recent years have become the subject of numerous lawsuits predicated on the claim that drug makers knowingly understated the addiction potential of their products to extract excessive profits from vulnerable consumers seeking efficacious and safe pain relief.^{38,39} Additional scholarship has shown the opioid epidemic to have largely resulted from well-intended medical efforts to more aggressively address consumer pain.^{4,40} A recent report by the National Academy of Medicine (NAM) noted that about half of opioid overdose deaths are related to medications obtained legally by prescription—including deaths from medications diverted to recreational or other illegal purposes—with one in three U.S. adults receiving a prescription opioid, and the total number of written prescriptions exceeding 225 million per annum.¹⁷

Quality measures in this domain are relevant to addressing the opioid crisis because they indirectly guide prevention through careful prescribing. Additionally, measures were identified in this domain which can be said to generally assess the quality of pain management. Studies and key informants emphasized that reductions in opioid prescribing for chronic pain have led to illicit opioid use or even suicidal ideation as patients struggle to cope with their unremitting pain.³²⁻³⁴ Despite the connection between legal supply channels and the opioid crisis, recent analytics caution that strategies which only reduce opioid prescribing will likely have limited impact on reducing overdoses, especially in the near term. This is largely because—absent tapering or non-opioid pain management—limitations on opioids can “push patients to fulfill their needs via illicitly obtained substances.”²²

Figure 1. Time-Series of U.S. Opioid-Related Deaths by Opioid Type



SOURCE: National Vital Statistics Mortality File.

Source: CDC: *Understanding the Epidemic*, 2019.

SUBDOMAIN: Pain Assessment

NQF found 21 measures in the pain assessment subdomain, consisting of measures related to the quantitation and description of pain in general, or related to a specific condition or treatment setting. Examples of specific conditions as assessed by pain measures include back pain, cancer, headache, heel pain, dementia, muscular dystrophy, osteoarthritis, and surgery. Measures were evaluated in various care settings including outpatient, hospitals, hospice, and nursing homes. It is notable that pain assessment is sometimes fairly straight-forward to assess via direct patient report, but other times is uncertain because of cognitive and communication difficulties related to a person’s illness or developmental stage.

The scan yielded limited healthcare performance measures that address the pain associated with many common pain conditions. For example, one key informant noted that bone pain, especially arthritis, was a common source of discomfort for patients, but did not receive sufficient attention in the broad field of pain measurement. Another key informant underscored the need for more education around safe opioid prescribing habits in all disciplines managing pain, including dentistry. The key informant indicated that dentistry, even oral surgery, can be practiced with far fewer opioids, a goal supported by recently issued American Dental Association guidelines.⁴¹ The TEP stated that another common area of

pain that is often overlooked is chronic fibromyalgia pain and other centralized pain syndromes. For fibromyalgia, specifically, potentially effective treatments other than or complementing opioids include rest, stress reduction, exercise, and non-opioid pain medications.⁴² A recent HHS report on pain management described over 30 distinctive non-opioid or complementary pain management approaches that offer broad options to tailor pain therapy.¹⁸

SUBDOMAIN: Pain Score Change

Twenty-one measures were found related to pain score change. The pain score change subdomain differs from pain assessment in that clinicians document changes in pain over time. This change over time is arguably of particular utility to assessing the efficacy of pain management because it partially adjusts each personal observation for subjective sensations of pain. No measure concepts were identified.

SUBDOMAIN: Time to Pain Management

There are four measures and one measure concept in this subdomain looking at total time elapsed until pain is addressed or brought under control. As is the case with pain score change, reducing time to pain control is not only an indicator of a desirable outcome, it also partially adjusts each personal observation for subjective sensations of pain, and it marks the time-efficiency of an intervention.

SUBDOMAIN: Quality of Life and Function

A total of 13 measures and one measure concept were identified which assess quality of life (QoL) and functional status (e.g., ability relative to expectations/history). QoL measures assess the impact of pain by considering patient-reported overall life quality, a construct that is measured by assessing how debilitating pain is regarding one's ability to enjoy life and function productively. Functional assessment measures with an additional pain component were grouped here as well. These measures include condition-specific assessments of levels of pain, function and overall QoL for headache, inner ear disorders, and spine disorders, among others.

SUBDOMAIN: Pain Care Plan

Within this subdomain, there are 10 measures and one measure concept. A pain care plan is a written document created by the clinician to address pain that may or may not include the use of opioids. These measures target conditions such as cancer and chronic headache, and settings including home health and surgical sites. Pain care plans include provisions for monitoring pain and function with time, adapting or altering therapies as necessary, and safely tapering persons off opioids as their pain is managed.

SUBDOMAIN: Non-opioid Pain Management

This subdomain contains nine measures and one measure concept focused on finding the right medications and other treatments for conditions where opioids are not the first line of therapy. It also includes measures documenting the exploration of options such as physical therapy and other nonpharmacologic interventions. Recent studies have indicated that opioids are often not the safest nor most effective method for managing chronic non-cancer pain,⁴³ and that other therapies for pain should

be considered when developing a pain management care plan including non-opioid pharmaceuticals, physical therapy, acupuncture, cognitive therapies, and other modalities.⁴⁴

SUBDOMAIN: Appropriate Opioid Analgesic Prescribing

NQF found 46 measures and 36 measure concepts within this subdomain. Measures of appropriate prescribing encapsulate a variety of prescriptive behaviors including suitable dose, formulation, and duration, as well as the avoidance of opioids for certain indications or co-prescribed medications. Measures in this subdomain include those that hold prescribers accountable for monitoring not only potential OUD, but also side-effects, adverse drug events, as well as therapeutic outcomes associated with opioid prescriptions. Also included are related concepts such as controlled substance agreements used to establish an understanding between the patient and clinician of what the goals of treatment are as well as baseline behavioral expectations for the patient related to the use of medication for the duration of therapy.

The TEP and key informants highlighted the need for measures focused on tapering off opioids. There may be references to tapering regimens in existing measures that focus on therapeutic agreements or follow-up well-visits, but this concept should be brought to the forefront of measurement around opioids. One key informant remarked that it should now be self-evident to prescribers that opioid-based pain management must be followed by a verified “exit plan” from that pharmacologic therapy. Additionally, no measures were found regarding safe storage and disposal of opioid containing medications—measures that might reduce the likelihood of opioids being obtained by individuals who were not prescribed the medication and may be likely to misuse them.

Domain 2: Treatment of Opioid Use Disorders (OUD)

Within the treatment of opioid use disorders domain, there were a total of 72 measures found and an additional 28 measure concepts as noted in Table 2. Measures and measure concepts were classified according to four subdomains: OUD screening, OUD treatment initiation, OUD treatment continuity, and psychiatric and/or other illness comorbidity. Notably, there were no measures connecting OUD to physical comorbidities, and thus integration or holistic care measures may be a gap area, even as such integration of services has long been a goal of the behavioral health field.⁴⁵

The metrics identified focus on prevention and treatment from detection through recovery, of diseases directly or commonly comorbid to OUD. Interventions in this domain are believed to be the center of the battle against the overdose epidemic because they directly address the increasing levels of use chronic misuse of opioids that places consumers at greatest risk for adverse events including overdose deaths.⁴⁶

Table 2. Measures and Measure Concepts for the Treatment of Opioid Use Disorders Domain

Subdomains	Measures	Measure Concepts
ODU Screening	18	5
ODU Treatment Initiation	15	10
ODU Treatment Continuity	10	8
Psychiatric and/or Other Illness Comorbidity	29	5
Total	72	28

Overarching Themes

The connection between the pain management and the treatment of OUD domains is well-established given the strong connection between opioid prescribing and subsequent opioid misuse and OUD. Recent studies suggest that up to 26 percent of persons initiating opioids for pain will misuse opioids, and up to 8 percent may develop a diagnosable OUD.⁴⁷ These rates are markedly above the less than 1 percent prevalence of OUD in the general population.^{48,49} Accordingly, measures of OUD screening and monitoring are of high importance in responding to the current opioid crisis. Early screening followed by efficient, brief intervention or referral to treatment has become one of the touchstones of high-quality, holistic care for SUD and psychiatric illnesses, especially.^{50,51}

Measures related to the screening and monitoring of OUD in the provision of care both for pain management and other behavioral health issues were prominent in the environmental scan. The need for such screening and ongoing surveillance is predicated on current evidence that a substantial treatment gap exists among persons with OUD. Only 1 of 10 persons with OUD receive the treatment they need, and 80 percent of those seeking help report an inability to access care.²¹ Measures of initiation of treatment for OUD have a natural sequential association with screening metrics. Once OUD is identified, it is critical to ensure accountability that care is recommended, and access is provided. A review of national survey data found that less than 20 percent of persons with OUD have used any SUD service in a given year.⁵² A separate analysis found that OUD medication treatment capacity only has the potential to cover about 61 percent of those in need.⁵³

Once OUD care is initiated, continuity of care becomes a central measurement issue. Guidelines for defining an approach encourage safer prescribing that integrate OUD treatment with pain management, an issue that was not well addressed by measures found in the environmental scan.¹⁷ Certain measures do capture best practices in OUD care continuity, such as the use of team-based approaches to SUD care, and systematic follow-up in care over time, including referrals to SUD specialists and other direct and ongoing treatments.¹⁷ This includes measures associated with medication-assisted treatment (e.g., buprenorphine, methadone)—the most evidence-based therapy for OUD, supported by major national and international organizations (e.g., National Institutes of Health, CDC, and the World Health Organization), and by numerous randomized trials demonstrating its efficacy to facilitate recovery and reduce overdoses.^{4,17}

While the scan yielded measures directly connected to larger behavioral health issues associated with OUD, both as precursors and corollaries, the TEP and key informants noted that there were few measures that address the complexity of issues surrounding recovery, remission, and relapse for OUD and people with behavioral health issues more generally. Addressing behavioral healthcare integration and coordination by connecting mental health, SUD, and physical care together with full consideration of transitions between different levels of care from prevention to recovery is presently of great interest to NQF’s Behavioral Health and Substance Use Disorder Standing Committee—a collection of experts convened by NQF to adjudicate endorsement of existing and emerging measures regarding that constellation of disorders.

SUBDOMAIN: OUD Screening

There are 18 identified measures and five measure concepts related to OUD screening, i.e., detection of the disorder in its early stages, or when a patient’s OUD status may otherwise be unknown to the clinician. The measures include direct questioning of patients related to their use of opioids, as well as indirect measures of potential opioid misuse drawing on patient records of prescriptions found in claims and through prescription drug monitoring programs. Measures in this category include screening for co-morbid SUD or psychiatric conditions, for SUD risk at inpatient intake, periodic urine and medical records reviews for evidence of SUD, and “risky behavior” assessments in adolescents and adults.

TEP members and key informants emphasized the need for screening especially in primary care, including dental care and pregnancy and perinatal treatment settings, and ensuring appropriate continued engagement upon identification of an OUD.

SUBDOMAIN: OUD Treatment Initiation

This subdomain includes 15 measures and 10 measure concepts looking at both pharmacologic and nonpharmacologic therapies related to OUD focusing on the appropriate response once OUD has been identified. Measures in this subdomain include several pertaining to initiation and early engagement after diagnosing an alcohol or other substance use disorder and simple screening for early or fully manifested SUD coupled with treatment appropriate for the diagnoses.

SUBDOMAIN: OUD Treatment Continuity

The 10 measures and eight measure concepts found for treatment continuity pertain to areas of care in the treatment of OUD including follow-up to hospitalization, medication supported withdrawal, treatment responsiveness, and continual assessment through recovery, remission, and relapses that interrupt those trajectories and goals. No measures were found for long-term follow-up, i.e., review of potential opioid misuse that emerges or persists months or years after a treatment course has concluded. This is the case even as OUD treatments, for example methadone or buprenorphine regimens, typically last for at least 12 months and are also known to be chronic and cycling.^{24,54} One key informant specifically noted that recovery should thus not be measured as a binary all or none phenomenon, but instead should be tracked with more incremental expectations because reductions in misuse represent important and favorable indicators.

TEP members identified the need for treatment retention, and specifically medication retention, to be more intentionally addressed through quality measurement. The TEP expressed concern that opioid medications (prescribed for either pain or OUD) are often tapered or otherwise discontinued too soon, as are behavioral treatments, often due to reimbursement and insurer determinations.

SUBDOMAIN: Psychiatric and/or Other illness Comorbidity

There are 29 measures in this subdomain as well as five measure concepts. Psychiatric conditions, such as depression and anxiety, and misuse of other harmful substances, such as alcohol or tobacco, have been linked to an increased risk of misuse or abuse of opioids. Additionally, SUDs correlate with increased risks for physical (somatic) illnesses including infectious diseases, cancer, and heart disease.⁵⁵⁻⁵⁸

While the measures and measure concepts in this subdomain are not always directly related to opioid use, it is important to consider comorbidities. Many people with OUD also have concomitant psychiatric conditions such as depression or anxiety, or such conditions may serve as antecedents to OUD.⁵⁵ In addition, people with OUD also typically have chemical dependencies with other harmful substances such as alcohol or tobacco.⁵⁹ One key informant pointed out that tobacco use among those with OUD is approximately 80 percent, and thus holistic quality care of such persons warrants consideration of both conditions.

Focusing on the impact of treatment on the individual's mental and physical well-being may be essential to sparing individuals from future misuse and OUD.⁴⁵ The standard of care for chronic illnesses such as OUD increasingly includes integrated approaches such as chronic health homes. These approaches are designed to manage OUD together with other behavioral and physical challenges that commonly impact the health of persons with OUD.⁶⁰ Despite these moves towards more integrated care, this environmental scan identified only two measure concepts that targeted such interconnections, one focused generally on behavioral health integration, and the other considering HIV-related care for those with OUD. Finally, it should be noted that the scan identified pain management measures, which at least screened for physical comorbidities that might influence the treatment of the pain. Though these pain measurement measures do not address OUD, they might inspire OUD measures that similarly address physical comorbidities as traceable components of the overall treatment endeavor.

Domain 3: Harm Reduction

There were few measures identified in this domain, with measures falling within one of two subdomains related to overdose and use of opioid reversal medication. The scan identified six measures and seven measure concepts in this domain as shown in Table 3.

Harm reduction strategies related to OUD include overdose prevention sites, needle exchange programs, respiratory antidotes to acute overdose (e.g., naloxone), and distribution of methods to detect the purity of illicit drugs.⁵ Harm reduction aims to prevent the eventual and extreme outcomes of mortality (related to overdose or serious infection), contrasting it with strategies that look closer to the problem by considering OUD or opioid prescribing as common precursors to overdoses. Of course, overdoses are not only "harms" tied to the opioid crisis, but they are fundamental (i.e., definitional) outcomes which need to be tracked somehow to verify quality improvement.

Table 3. Measures and Measure Concepts for the Harm Reduction Domain

Subdomains	Measures	Measure Concepts
Overdose	5	4
Opioid Reversal Drug Prescription	1	3
Total	6	7

Overarching Themes

The well-known propensity for opioids to produce tolerance, dependence, and abuse is an overarching theme in this and other domains of the scan.⁶¹ This is complicated by the narrow therapeutic index and potential for deadly toxicity found in this drug class.⁶² Calls for the co-prescribing of naloxone (as an emergency antidote to those at risk of overdose) have likely led to some of the measures found in this environmental scan. Across the U.S., naloxone dispensing increased more than 12-fold between 2010 and 2016,⁶³ providing the life-saving antidote for an estimated 26,123 overdoses in 2014 alone.⁶⁴ Moreover, well over half of all states in the U.S. have passed laws which expand access to naloxone, and otherwise limit liability to those who use it to revive someone they suspect may have overdosed on an opioid.⁶⁵

The opioid epidemic is in large part iatrogenic, yet the ongoing prevalence of OUD with the accompanying deaths has distinctly shifted to illicit channels that include high and uncertain potency of synthetic opioids (e.g., fentanyl) commonly used to lace heroin.²¹ This shift implies that metrics of naloxone co-prescription with opioids are necessary, but they are insufficient to prevent the large number of deaths associated with fentanyl-laced heroin, a phenomenon presumably removed from the influence of most opioid prescribers. The scan did not produce measures that address solutions to this critical issue of fentanyl-associated overdose, such as access to, or education regarding, the use of fentanyl test strips.⁶⁶

The environmental scan did not return measures of access to and capacity for harm reduction related interventions. This is of concern because the limited capacity of the treatment system has pressured some emergency departments and first-responders to advocate for “three strikes” rules which would deny treatment to those needing repeated life-saving interventions.¹⁷ Measures associated with other harm reduction interventions were also gaps, including for more well-established processes such as needle and syringe services which can reduce the harm associated with disease transmission, such as HIV and hepatitis. This is even as data from a 2016 CDC analysis indicates that only 54 percent of persons using injection drugs also use syringe services.⁴³

SUBDOMAIN: Overdose

Measures in this subdomain are focused on issues related to the direct assessment of opioid overdose frequency. Five measures and four measure concepts were found. These include fatal and nonfatal hospital-based overdoses and emergency department visits because of other adverse reactions to opioids. The four measure concepts related to the percentage of opioid overdoses treated in emergency

departments, hospital rates of opioid respiratory depression, overdose deaths from synthetic opioids, and overdose deaths from any opioid.

SUBDOMAIN: Opioid Reversal Drug Prescription

The environmental scan yielded a single measure related to naloxone prescription post -discharge from opioid overdose. In addition, three measure concepts were found related to naloxone prescriptions for OUD patients upon discharge, for patients on long-term opioid therapy, and for patients on high-dose opioid therapy.

Domain 4: Social Issues

The four measures and one measure concept found in this domain pertained to a small subset of social issues connected to opioids and opioid use disorder as shown in Table 4. Specifically, these subdomains include violence, health literacy, opioid burden and criminal justice. Social issues including those related to overall mental health, education, economic status, stigma, and criminal justice issues were sparse in the measures identified.

Table 4. Measures and Measure Concepts for the Social Issues Domain

Subdomains	Measures	Measure Concepts
Violence	2	0
Health Literacy	1	0
Opioid Burden	0	1
Criminal Justice	1	0
Total	4	1

Overarching Themes

Many of the measure concepts and ideas that would fall within this domain are inherently challenging to operationalize or otherwise assess for accountability purposes. For example, reports on approaches to the opioid crisis have called for reduction in stigma via public relations strategies that encourage the mass media, government, and medical practitioners to diminish mainstream society’s tendency to dismiss those with OUDs as lost causes or morally corrupt, or to reject evidence-based treatments like buprenorphine, methadone, and naloxone.^{21,30,31} Measuring changes in such abstract attitudes and actions is difficult but possible through patient reports regarding their clinical experiences, including assessments of whether or not a provider adopted nonprejudicial language (e.g., “a person with an OUD” rather than “an addict”).⁴ Additionally, stigma and related constructs might be measured via knowledge tests of providers and accountable policymakers to reduce stereotypes about OUD.

Related to stigma and risk are measurement ideas connected to criminal justice reform as a key priority to address the opioid epidemic. Such reform, for example, could expand treatment options in lieu of jail time, provide treatment in jails and prisons as necessary, and train police officers and other first-responders to better cope with the acute challenges of opioid misuse. Another important indicator identified in the environmental scan included the provision of OUD treatment on admission and discharge from criminal justice settings.^{21,67} Several states have recently introduced laws to provide

medication treatment in jails and prisons with favorable results. In Rhode Island, rates of overdose among released inmates were 60 percent lower if OUD treatment was made available prior to release.⁶⁸

The TEP identified the absence of measures related to neonatal abstinence syndrome (NAS) as a measure gap within the environmental scan.⁶⁹ The TEP also recognized measure gaps related to social determinants of health, specifically potential measures for factors such as employment, housing, and criminal justice involvement. One recent study found that homeless persons with SUD who entered a housing intervention had greatly reduced (by 53 percent) financial needs (for temporary housing, jail, and treatment services) compared to those who were wait-listed controls for the same housing program.⁷⁰ While social determinant issues were mostly absent from the environmental scan, they are well known to be important antecedents and consequences of OUDs and overdoses.^{4,21,22,29} Several key informants emphasized the need to track social determinants of health and to incorporate them into the measurement of opioid use and misuse.

SUBDOMAIN: Violence

The environmental scan included two measures related to violence: general healthcare screening for intimate partner violence and violence risk screening at inpatient psychiatric facility (IPF) admission. Neither of these measures are specific to OUD but were selected for this scan because they explicitly assess interpersonal violence. Such exposure to violence represents both a complicating comorbidity, and a risk factor for developing or exacerbating SUD.^{71,72}

SUBDOMAIN: Health Literacy

The environmental scan also identified the social issue of health literacy. A single metric associated with this measurement area was identified. As with the violence measures above, this measure is not specific to OUD or pain management directly; however, it represents a patient-centered assessment of health communication competency that has potential to inspire measures related to pain or OUD treatments. While this general health literacy measure is important, also needed is evaluation of the extent to which patients initiating pain or OUD treatments are well-educated about the risks of opioids, including the potential physical and behavioral health impacts and realistic expectations about future drug use and recovery. This includes proper patient education and counseling for persons with pain and OUD as co-occurring chief complaints.⁷³

SUBDOMAIN: Opioid Burden

One measure concept was found related to the total economic burden associated with the opioid crisis. This measure concept considers healthcare, productivity, and criminal justice costs in an effort to assess the full costs associated with opioid misuse and OUD. It is estimated that OUD costs the U.S. economy nearly \$100 billion dollars each year based on the three cost concepts noted above, and well over twice that amount if one considers the direct “monetary value” of a human life.^{35,36}

SUBDOMAIN: Criminal Justice

The environmental scan yielded a single state-specific measure related to criminal justice involvement. The TEP and key informants emphasized the need to ensure that persons in jail receive medication for OUD (methadone, buprenorphine, naltrexone) and further receive transition care support when they

are released. Moreover, the environmental scan found that OUD and recidivism risk are jointly and separately linked to use of the following types of services which thus constitute important factors to measure: stable housing, employment, meaningful daily activities, and supportive peers.^{74,75}

Next Steps

Measurement is an essential tool to improve opioid use nationwide, both for the management of pain and the reduction of the severe consequences associated with opioid misuse and abuse. Performance measurement offers an opportunity to assess, support, and incentivize the reduction of the adverse impact of opioids in U.S. healthcare that have contributed to the opioid crisis. This environmental scan was conducted to identify impactful measures and potential measure gaps associated with opioids and opioid use disorder.

The scan identified over 200 measures and measure concepts that directly or indirectly relate to the opioid overdose epidemic presently challenging the U.S. Both opioid use for pain management and OUD treatment issues were considered in this scan. Though many measures were found across four organizing domains of pain management, treatment of OUD, harm reduction, and social issues, many gaps were also identified, including a dearth of measures that are available to assess quality of life and function, long-term recovery, comorbidities to OUD, harm reduction strategies, and economic and cultural issues including housing supports and stigma.

Over the coming weeks the convened NQF TEP will react to this scan with the goal of validating or improving upon its methods and conclusions. Additional gaps will be identified and then prioritized for inclusion in the TEP's final report. The final report will also include guidance to CMS on opioid and OUD metrics for use in five federal quality and performance programs: the Merit-Based Incentive Payment System (MIPS), alternative payment models (APM), the Medicare Share Savings Program (MSSP), the Hospital Inpatient Quality Reporting Program (IQR), and the Hospital Value-Based Purchasing Program (VBP). The overall goal of this measurement endeavor is to reduce mortality and morbidity related to opioid use in the United States.

References

- 1 Centers for Disease Control and Prevention (CDC). Understanding the Epidemic. <https://www.cdc.gov/drugoverdose/epidemic/index.html>. Published December 2018. Last accessed June 2019.
- 2 Allen G, Kelly A. Trump Administration Declares Opioid Crisis A Public Health Emergency. *The National Public Radio*. <https://www.npr.org/2017/10/26/560083795/president-trump-may-declare-opioid-epidemic-national-emergency>. Published October 26, 2017. Accessed June 17, 2019.
- 3 Mershon E. How states have used emergency declarations to fight the opioid epidemic. <https://www.statnews.com/2017/08/09/opioids-state-of-emergency-states/>. Accessed June 17, 2019.
- 4 Olsen Y, Sharfstein JM. *The Opioid Epidemic: What Everyone Needs to Know*. Oxford, New York: Oxford University Press; 2019.
- 5 Jiang Y, McDonald J, Wilson MEL, et al. Rhode Island Unintentional Drug Overdose Death Trends and Ranking – Office of the State Medical Examiners Database. *RI Med J*. 2013;101(1):33-36.
- 6 Saloner B, Barry CL. Ending the Opioid Epidemic Requires A Historic Investment in Medication-Assisted Treatment. *J Policy Anal Manag*. 2018;37(2). <https://onlinelibrary.wiley.com/doi/abs/10.1002/pam.22047>. Last accessed June 2019.
- 7 Katz J, Sanger-Katz, Margot. ‘The Numbers Are So Staggering.’ Overdose Deaths Set a Record Last Year. *The New York Times*. <https://www.nytimes.com/interactive/2018/11/29/upshot/fentanyl-drug-overdose-deaths.html>. Accessed June 17, 2019.
- 8 McCabe SE, West BT, Jutkiewicz EM, et al. Multiple DSM-5 substance use disorders: A national study of US adults. *Hum Psychopharmacol*. 2017;32(5).
- 9 Substance Abuse and Mental Health Services Administration (SAMHSA). *2017 NSDUH Annual National Report*.; 2017. <https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report>. Last accessed June 2019.
- 10 National Institute on Drug Abuse (NIDA). The Science of Drug Use and Addiction: The Basics. <https://www.drugabuse.gov/publications/media-guide/science-drug-use-addiction-basics>. Published July 2018. Last accessed July 2019.
- 11 American Society of Addiction Medicine (ASAM). *Definition of Addiction*.; 2011. <https://www.asam.org/quality-practice/definition-of-addiction>. Last accessed June 2019.
- 12 National Institute on Drug Abuse (NIDA). *How Science Has Revolutionized the Understanding of Drug Addiction*. <https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/preface>. Last accessed June 2019.
- 13 American Psychiatric Association (APA). *Diagnostic and Statistical Manual of Mental Disorders*. Fifth Edition. Washington, DC: American Psychiatric Association; 2013.

- 14 Substance Abuse and Mental Health Services Administration. Mental Health and Substance Use Disorders. <https://www.samhsa.gov/find-help/disorders>. Published January 14, 2019. Last accessed April 2019.
- 15 HHS. *Facing Addiction in America: The Surgeon General's Spotlight on Opioids*. Washington, DC: Office of the Surgeon General; 2018:1-40. <https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf>.
- 16 Puntillo K, Naidu RK. Measurement of Chronic Pain and Opioid Use Evaluation in Community-Based Persons with Serious Illnesses. *J Palliat Med*. 2018;21(S2):S43-S51.
- 17 National Academy of Medicine (NAM), ed. *First, Do No Harm: Marshaling Clinician Leadership to Counter the Opioid Epidemic*. Washington, DC: National Academy of Medicine; 2017.
- 18 Assistant Secretary for Health (ASH). *Report on Pain Management Best Practices*: HHS; 2018. <https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html>. Last accessed July 2019.
- 19 Morris C, Green KE, Chimuma, MAT LL. A Rasch analysis of the Current Opioid Misuse Measure for patients with chronic pain. *J Opioid Manag*. 2018;14(1):9.
- 20 Interagency Pain Research Coordinating Committee. National Pain Strategy Overview. <https://www.iprcc.nih.gov/National-Pain-Strategy/Overview>. Published May 2017. Last accessed July 2019.
- 21 Saloner B, McGinty EE, Beletsky L, et al. A Public Health Strategy for the Opioid Crisis. *Public Health Rep*. 2018;133(1_suppl):24S-34S.
- 22 Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. *Am J Public Health*. 2018;108(2). <https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2017.304187>. Last accessed June 2019.
- 23 Pitt AL, Humphreys K, Brandeau ML. Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic. *Am J Public Health*. 2018;108(10):1394-1400.
- 24 Sharfstein JM, Olsen Y. Making Amends for the Opioid Epidemic. *JAMA*. 2019;321(15):1446-1447.
- 25 Barry C, Sherman S, Stone E, et al. Arguments supporting and opposing legalization of safe consumption sites in the U.S. *Int J Drug Policy*. 2019;63:18-22.
- 26 Center on Addiction. *Ending the Opioid Crisis: A Practical Guide for State Policymakers*; 2017. <https://www.centeronaddiction.org/addiction-research/reports/ending-opioid-crisis-practical-guide-state-policymakers>. Last accessed July 2019.
- 27 King NB, Fraser V, Boikos C, et al. Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: a systematic review. *Am J Public Health*. 2014;104(8):e32-42.
- 28 Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. *Am J Public Health*. 2018;108(2):182-186.
- 29 Case A, Deaton A. Mortality and Morbidity in the 21st Century. *Brook Pap Econ Act*. 2017;2017(1):397-476.

- 30 Kennedy-Hendricks A, Barry CL, Gollust SE, et al. Social Stigma Toward Persons With Prescription Opioid Use Disorder: Associations With Public Support for Punitive and Public Health-Oriented Policies. *Psychiatr Serv Wash DC*. 2017;68(5):462-469.
- 31 Yang LH, Wong LY, Grivel MM, et al. Stigma and Substance Use Disorders: an International Phenomenon. *Curr Opin Psychiatry*. 2017;30(5):378-388.
- 32 Cohn M. Fatal overdoses decline in Maryland for first time in years as fentanyl-related deaths dip in first quarter. *The Baltimore Sun*. <https://www.baltimoresun.com/health/bs-hs-opioid-deaths-dip-20190611-story.html>. Published June 11, 2019. Accessed June 18, 2019.
- 33 Musumeci M, Tolbert J. Federal Legislation to Address the Opioid Crisis: Medicaid Provisions in the SUPPORT Act. *Henry J Kais Fam Found*. October 2018. <https://www.kff.org/medicaid/issue-brief/federal-legislation-to-address-the-opioid-crisis-medicaid-provisions-in-the-support-act/>. Last accessed April 2019.
- 34 Medicaid and CHIP Payment and Access Commission. Payment for services in institutions for mental diseases (IMDs). <https://www.macpac.gov/subtopic/payment-for-services-in-institutions-for-mental-diseases-imds/>. Last accessed July 2019.
- 35 Florence CS, Zhou C, Luo F, et al. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. *Med Care*. 2016;54(10):901.
- 36 Council of Economic Advisors. *The Underestimated Cost of the Opioid Crisis*.; 2017. <https://www.whitehouse.gov/briefings-statements/cea-report-underestimated-cost-opioid-crisis/>. Last accessed June 2019.
- 37 Roubein R. Warren, Cummings seek \$100B to fight opioid epidemic. <https://thehill.com/business-a-lobbying/383787-warren-cummings-seek-100b-to-fight-opioid-epidemic>. Published April 18, 2018. Last accessed June 2019.
- 38 Sackler family sued again over toll of prescription opioids. *The Baltimore Sun*. <https://www.baltimoresun.com/news/nation-world/sns-bc-nj--opioid-crisis-lawsuit-20190530-story.html>. Accessed June 18, 2019.
- 39 Hoffman J. Groundwork Is Laid for Opioids Settlement That Would Touch Every Corner of U.S. *The New York Times*. <https://www.nytimes.com/2019/06/14/health/opioids-lawsuit-settlement.html>. Published June 14, 2019. Accessed June 18, 2019.
- 40 National Academies of Science, Engineering and Medicine. *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research*.; 2011. <http://www.nationalacademies.org/hmd/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx>. Last accessed June 2019.
- 41 American Dental Association (ADA). American Dental Association Announces New Policy to Combat Opioid Epidemic. <https://www.ada.org/en/press-room/news-releases/2018-archives/march/american-dental-association-announces-new-policy-to-combat-opioid-epidemic>. Published March 2018. Last accessed June 2019.
- 42 Mayo Clinic. Fibromyalgia - Symptoms and causes. <https://www.mayoclinic.org/diseases-conditions/fibromyalgia/symptoms-causes/syc-20354780>. Last accessed June 2019.

- 43 Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. *MMWR Recomm Rep*. 2016;65.
<https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm>. Last accessed June 2019.
- 44 National Academies of Science, Engineering and Medicine. *Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use*.
<https://www.nap.edu/read/24781/chapter/1>. Last accessed June 2019.
- 45 Pincus HA, Scholle SH, Spaeth-Rublee B, et al. Quality Measures For Mental Health And Substance Use: Gaps, Opportunities, And Challenges. *Health Aff Proj Hope*. 2016;35(6):1000-1008.
- 46 Williams AR, Nunes EV, Bisaga A, et al. Development of a Cascade of Care for Responding to the Opioid Epidemic. *Am J Drug Alcohol Abuse*. 2019;45(1):1-10.
- 47 Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies. *N Engl J Med*. 2016;374(13):1253-1263.
- 48 Substance Abuse and Mental Health Services Administration (SAMHSA). Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. <https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.htm>. Published 2017. Last accessed July 2019.
- 49 National Institute on Alcohol Abuse and Alcoholism (NIAAA). Rates of nonmedical prescription opioid use and opioid use disorder double in 10 years. National Institute on Alcohol Abuse and Alcoholism (NIAAA). <https://www.niaaa.nih.gov/news-events/news-releases/rates-nonmedical-prescription-opioid-use-and-opioid-use-disorder-double-10>. Published June 2016. Last accessed July 2019.
- 50 Substance Abuse and Mental Health Services Administration (SAMHSA). Resources for SBIRT. <https://www.samhsa.gov/sbirt/resources>. Published April 3, 2014. Last accessed June 2019.
- 51 Centers for Disease Control and Prevention (CDC). CDC’s Alcohol Screening and Brief Intervention Efforts. Centers for Disease Control and Prevention. <https://www.cdc.gov/ncbddd/fasd/alcohol-screening.html>. Published December 2018. Last accessed July 2019.
- 52 Saloner B, Karthikeyan S. Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. *JAMA*. 2015;314(14):1515-1517.
- 53 Jones CM, Campopiano M, Baldwin G, et al. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. *Am J Public Health*. 2015;105(8):e55-e63.
- 54 Substance Abuse and Mental Health Services Administration (SAMHSA). Methadone. <https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone>. Published June 16, 2015. Last accessed July 2019.
- 55 Scherrer JF, Salas J, Copeland LA, et al. Increased Risk of Depression Recurrence After Initiation of Prescription Opioids in Noncancer Pain Patients. *J Pain*. 2016;17(4):473-482.
- 56 Edwards K, Vowles KE, Witkiewitz K. Co-use of Alcohol and Opioids. *Curr Addict Rep*. 2017;4(2):194-199.

- 57 Preedy VR. *Neuropathology of Drug Addictions and Substance Misuse Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids*. Academic Press; 2016.
- 58 National Institute on Drug Abuse. Common Comorbidities and Substance Use Disorders. <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/introduction>. Published February 2018. Last accessed July 2019.
- 59 Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey replication. *Arch Gen Psychiatry*. 2005;62:11.
- 60 Clemans-Cope L, Wishner JB, Allen EH, et al. Experiences of three states implementing the Medicaid health home model to address opioid use disorder-Case studies in Maryland, Rhode Island, and Vermont. *J Subst Abuse Treat*. 2017;83:27-35.
- 61 Morgan MM, Christie MJ. Analysis of Opioid Efficacy, Tolerance, Addiction and Dependence from Cell Culture to Human. *Br J Pharmacol*. 2011;164(4):1322-1334.
- 62 Opioid Pharmacokinetic Drug-Drug Interactions. https://www.ajmc.com/journals/supplement/2011/a370_11sep/a370_11sep_overholser_s276tos287. Last accessed June 2019.
- 63 Jones CM, Lurie PG, Compton WM. Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013. *Am J Public Health*. 2016;106(4):689-690.
- 64 National Institute on Drug Abuse (NIDA). Medications to Treat Opioid Addiction. <https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview>. Published June 2018. Last accessed June 2019.
- 65 Energy and Commerce Committee. *Hearing on "What Is the Federal Government Doing to Combat the Opioid Abuse Epidemic?" Subcommittee on Oversight and Investigations (May 1, 2015)*.; 2015. <https://energycommerce.house.gov/committee-activity/hearings/hearing-on-what-is-the-federal-government-doing-to-combat-the-opioid>. Last accessed June 2019.
- 66 Krieger MS, Goedel WC, Buxton JA, et al. Use of Rapid Fentanyl Test Strips among Young Adults Who Use Drugs. *Int J Drug Policy*. 2018;61:52-58.
- 67 Centers for Disease Control and Prevention (CDC). Infectious Diseases, Opioids and Injection Drug Use in Persons Who Inject Drugs. <https://www.cdc.gov/pwid/opioid-use.html>. Published April 2019. Last accessed June 2019.
- 68 Green T, Clarke J, Brinkley-Rubenstein L. Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. *JAMA Psychiatry*. 2018;75(4):405-407.
- 69 Ho J. Preventing Neonatal Abstinence Syndrome within the Opioid Epidemic: A Uniform Facilitative Policy. *Fac Publ*. September 2016. https://scholarship.law.umassd.edu/fac_pubs/193.
- 70 Larimer ME, Malone DK, Garner MD, et al. Health Care and Public Service Use and Costs before and after Provision of Housing for Chronically Homeless Persons with Severe Alcohol Problems. *JAMA*. 2009;301(13):1349-1357.

- 71 Desmarais SL, Gray JS, Rade CB, et al. Medication-assisted treatment and violent outcomes in community-based offenders with alcohol and drug use problems. *Psychol Violence*. 2016;6(3):378-389.
- 72 Hughes K, Bellis MA, Hardcastle KA, et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. *Lancet Public Health*. 2017;2(8):e356-e366.
- 73 Rogers AH, Bakhshaie J, Orr MF, et al. Health Literacy, Opioid Misuse, and Pain Experience Among Adults with Chronic Pain. *Pain Med*. <https://academic.oup.com/painmedicine/advance-article/doi/10.1093/pm/pnz062/5425909>. Last accessed June 2019.
- 74 Mallik-Kane K, Jannetta J, Hatry H. Measuring Progress in Connecting Criminal Justice to Health. *Urban Inst*. March 2018:62.
- 75 Substance Abuse and Mental Health Services Administration (SAMHSA). Medication-Assisted Treatment (MAT) in the Criminal Justice System: Brief Guidance to the States. <https://store.samhsa.gov/product/Medication-Assisted-Treatment-MAT-in-the-Criminal-Justice-System-Brief-Guidance-to-the-States/PEP19-MATBRIEFCJS>. Published March 2019. Last accessed June 2019.

Appendix A: Committee Members, NQF Staff, and Federal Liaisons

Committee Members

Brandon Marshall, PhD

Associate Professor of Epidemiology at Brown University
Providence, RI

Jeff Schiff, MD, MBA

Medical Director, Medicaid at the Minnesota Department of Human Services
St. Paul, MN

Anika Alvanzo, MD, MS

Assistant Professor at Johns Hopkins University, Associate Medical Director at Addiction Treatment Services and the Center for Addiction and Pregnancy
Baltimore, MD

Michael Ashburn, MD, MPH, MBA

Professor of Anesthesiology and Senior Fellow of Leonard Davis Institute of Health Economics at University of Pennsylvania
Philadelphia, PA

Antje Barreveld, MD

Assistant Professor of Anesthesiology at Tufts University School of Medicine, Medical Director of Pain Management Services
Newton, MA

Patty Black, BS

Patient Advocate
Eugene, OR

Jeannine Brant, PhD, APRN, AOCN, FAAN

Oncology Clinical Nurse Specialist, Pain Consultant and Research Scientist, Billings Clinic
Billings, MT

Caroline Carney, MD, MSc, FAMP, CPHQ

Chief Medical Officer, Magellan Rx
Virginia Beach, VA

Anthony Chiodo, MD, MBA

Associate Chair of PMR, Service Chief for Spine Program, Michigan Medicine
Ann Arbor, MI

Jettie Eddleman, BSN, RN

Director of Operations, Rural and Community Health Institute
College Station, TX

Maria Foy, PharmD, BCPS, CDE

Clinical Pharmacy Specialist, Abington Jefferson Health
Abington, PA

Jonathan Gleason, MD

Chief Quality Officer and Medical Director for Risk Management, Carilion Clinic
Roanoke, VA

Anita Gupta, DO, PharmD, MPP

Senior Vice President, Medical Strategy and Government Affairs, Heron Therapeutics
San Diego, CA

Mark Hurst, MD

Assistant Director of Clinical Services, Ohio Department of Mental Health and Addiction Services
Columbus, Ohio

Katie Jordan, OTD, OTR/L

Associate Chair of Clinical Occupational Therapy Service
Los Angeles, CA

Navdeep Kang, PsyD

Clinical Psychologist and Director of Operations for Behavioral Health, Mercy Health
Batavia, Ohio

Sarah Melton, PharmD, BCPP, BCACP, FASCP

Professor of Pharmacy Practice at Gatton College of Pharmacy at East Tennessee State University
Johnson City, TN

Gary Mendell, MBA

CEO of Shatterproof
New York, NY

Darlene Petersen, MD

Board-certified physician in addiction medicine, Revere Health
Roy, UT

Laura Porter, MD

Patient Advocate
Cheverly, MD

James Rhodes, PharmD, MBA, BCPS, BCGP

Director of Enterprise Opioid Strategy, Humana
Geriatric Pharmacist and Pharmacotherapy Specialist
Crestwood, KY

Darshak Sanghavi, MD

Chief Medical Officer and Senior Vice President of Translation, Optum Labs
Cambridge, MA

Evan Schwarz, MD, FACEP, FACMT

Medical Toxicology, Chief and Associate Professor of Emergency Medicine, BJC HealthCare
St. Louis, MO

Norris Turner

Vice President of Strategic Alliances and Measure Implementation, Pharmacy Quality Alliance
Alexandria, VA

Sarah Wakeman, MD, FASEM

Addiction Medicine Physician, Assistant Professor of Medicine at Harvard Medical School
Medical Director for Mass General Hospital Substance Use Disorder Initiative
Charlestown, MA

Sarah Wattenberg, MSW

Director of Quality and Addiction Services, National Association for Behavioral Healthcare
Washington, DC

Arthur Robin Williams, MD, MBE

Assistant Professor of Psychiatry, Columbia University Department of Psychiatry
New York, NY

Bonnie Zickgraf, BSN, RN, CMCN

Manager, URAC
Davenport, FL

NQF Staff

Elisa Munthali, MPH

Senior Vice President, Quality Measurement

Samuel Stolpe, PharmD, MPH

Senior Director

Michael Abrams, MPH, PhD

Senior Director

Wunmi Isijola, MPH

Senior Managing Director

Poonam Bal, MHSA

Senior Project Manager

Vaishnavi Kosuri, MPH

Project Analyst

CMS Liaisons

Sophia Chan, PhD

Centers for Medicare & Medicaid Services

Maria Durham, MBA

Centers for Medicare & Medicaid Services

Marsha Smith, MD

Centers for Medicare & Medicaid Services

Patrick Wynne

Centers for Medicare & Medicaid Services

Ellen Blackwell

Centers for Medicare & Medicaid Services

Helen Dollar-Maples

Centers for Medicare & Medicaid Services

Federal Liaisons

Robert Anthony

Office of the National Coordinator for Health Information Technology

Sarah Duffy, PhD

National Institutes of Health

Elisabeth Kato, MD, MRP

Agency for Healthcare Research and Quality

SreyRam Kuy, MD, MHS, FACS

Veterans Affairs

Scott Smith, PhD

Office of the Assistant Secretary for Planning and Evaluation

Judith Steinberg, MD, MPH

Health Resources and Services Administration

Linda Streitfeld, MPH

Centers for Medicare & Medicaid Services

Appendix B: Environmental Scan Strategy

Purpose

This appendix details the NQF team's approach to conducting the environmental scan of measures for the Opioid and Opioid Use Disorder Quality Measures project. The environmental scan addressed the current state of opioid-related healthcare quality measures to support the work of the TEP. The TEP will use the scan to identify gaps and provide recommendations on the inclusion of measures in various federal programs and on future measure development efforts regarding challenges posed by opioid use in the U.S.

Research Questions

The following three research questions guided the environmental scan. These questions helped to focus the NQF team's research efforts and ensure the information sources collected are relevant to the project objectives.

- What current or emerging quality of care measurements (i.e., metrics, indicators) exist regarding the use of opioids for pain management or the treatment and prevention of opioid-related abuse, dependence, and death?
- What are the major current and emerging concepts (i.e., facts and science-based theories) regarding opioid use and misuse which can be used to evolve associated quality measurement?
- What directions should quality measurement science take to advance the battle against the U.S. opioid overdose epidemic, i.e., where are the apparent and important gaps?

Scope

The environmental scan began with a broad search and gradually decreased in scope as certain settings, types of measures, or concepts were prioritized. The TEP and key informants guided the prioritization process. The NQF team only collected measures for which there is enough information to understand how the measure should be used (e.g., what is being measured, where does measurement occur, who is the target for measurement, etc.). This report synthesized information from the following five sources:

1. Peer-reviewed, scientific literature (capturing elements found in Table 1)
2. 'Grey' scientific literature (i.e., technical reports, from reputable sources) (capturing elements found in Table 1)
3. Quality measurement databases (e.g., Quality Positioning System QPS) (capturing elements found in Appendix D and E)
4. State laws responding to the opioid crisis (capturing elements found in Table 2)
5. Key informant interviews (See Appendix C for more information)

Sources

The NQF team conducted various searches and reviews as specified in this appendix. Key informants were used to identify exemplary literature as well as existing and emerging measures. The search was an iterative process with constant opportunities for feedback from the project team and the Technical Expert Panel. The environmental scan included, but was not limited to a review of the peer-reviewed literature and grey literature and:

1. Academic Search
 - a. Pubmed (NLM)
2. Internet searches at the following sites:
 - a. HHS agencies
 - i. Administration for Children and Families
 - ii. Administration for Community Living
 - iii. Agency for Healthcare Research and Quality
 - iv. Agency for Toxic Substance and Diseases Registry
 - v. Assistant Secretary for Health
 - vi. Assistant Secretary for Planning and Evaluation
 - vii. Assistant Secretary for Preparedness and Response
 - viii. Center for Disease Control and Prevention
 - ix. Centers for Medicare & Medicaid Services
 - x. Food and Drug Administration
 - xi. Health Resources and Services Administration
 - xii. Indian Health Service
 - xiii. National Institutes of Health
 - xiv. Office of the National Coordinator for Health Information Technology
 - xv. Substance Abuse and Mental Health Services Administration
 - b. National Academy of Medicine
 - c. Commonwealth Fund
 - d. Kaiser Family Foundation
 - e. QPS
 - f. Government Accountability Office

The following publications were also reviewed to compile a compendium of relevant measures and measure concepts:

1. NQF ([Quality Positioning System](#), [Online Product Update System](#))
2. CMS Measures Inventory Tool (CMIT)
3. Qualified Clinical Data Registries (QCDR)

Search Parameters

The NQF team used the parameters defined in Table B1 to conduct the search. The team used specific “terms” or “strings” to search for information sources. Databases were searched using combinations and variations of the example search terms below. NQF also used relevant MeSH terms. The NQF team refined the search parameters when appropriate as additional information was gathered.

Table B1. Literature Search Parameters

Included	Excluded
<ul style="list-style-type: none"> • Published/passed on or after January 1, 2013* AND • Contains the strings: “opioid” OR “opiate” OR “pain management” OR “substance use disorder” OR “addict” AND • Contains the strings: “metric” OR “measure” OR “indicator” OR “survey” AND • Contains the strings: “Quality” OR “Health” 	<ul style="list-style-type: none"> • Published before 2013 and not current • Not available in English • Case studies • Publications focusing exclusively on tobacco, pharmacology or molecular levels

* the year when synthetic opioid deaths first started to rise markedly.

Operational Definitions

(for use in completing/categorizing the various evidentiary reviews)

- **Outcomes measure:** a measure that assesses a health state (e.g., death, lab results, illness remission)
- **Process measure:** a measure that assesses an action that is presumed to be connected to quality of care (e.g., a treatment, screening, scheduling)
- **Structural measure:** a measure that assesses resources available for care (e.g., supplies of naloxone, equipment, facilities, personnel, procedures)
- **Measure concept:** a quality measure that has not been fully specified and tested, such as one that draws on an existing or potential assessment tool or instrument that includes a planned target and population
- **Instrument:** an assessment tool such as a survey, scale, questions, etc.
- **Opioid:** this term encompasses the family of psychoactive pharmaceutical analgesics with a chemical structure similar to morphine, used primarily to treat pain and has high abuse and addiction potential.
- **Substance abuse or misuse:** the use of a pharmaceutical or alcohol in a way that is risky (i.e., contraindicated, excessive, underage, otherwise illicit)
- **Substance use disorder:** dependence on one or more legal or illegal drugs (including alcohol and tobacco) that is marked by increasing reliance on those substances, and negative behavioral change (e.g., frequent intoxication and lability).
- **Pain management:** The active treatment of acute or chronic pain under medical (surgical, dental, primary care) prescription or supervision, including the use of nonpharmaceutical interventions (e.g., physical therapy.) and the use of interventions in the context of palliative care.

- **Access:** the timely use of personal health services to achieve the best possible outcomes.

State Law Reviews

State laws and policies germane to the opioid epidemic in the U.S. were studied via a perusal of LexisNexis database items obtained using the search terms “state laws opioids” and constrained to those since 2013. Grey and scientific literature items were also used to consider state laws. Table B2 summarizes the types of items and information found by this search strategy. Specific reference to such items/information are made in the environmental scan if deemed useful. Overall, each of the laws or policies identified corresponds to one of the measure domains used to guide this environmental scan (see the last column). Accordingly, these laws generally did not add any new measurement concepts or ideas to the scan. The table shows how widespread state-based initiatives are with regards to the opioid crisis.

Table B2. Summary of State Laws and Policies that Directly Addressed the Opioid Crisis*

Description	States (n**)	Examples	Domain/Subdomain
Education/Awareness Campaigns	12		Prevention
School and Community Prevention Programs	6	Maryland now requires drug prevention programs in grades 3-12.	Prevention
Prescription Drug Monitoring Programs	49	Five states have published evaluations of these programs. Some states have inter-state data sharing networks.	Pain management
Safe prescribing initiatives	11	7 day dispensing limits; training for providers	Pain management
Prescription drug take-back programs	7	In 2017 MA became the first state to finance safe disposal of medications.	Pain management
Professional training in SUD care	3	School and child welfare professionals educated about SUDs	OUD treatment
Screening and referral initiatives	4	MA law from 2016 requires verbal screening in schools.	OUD treatment
Naloxone access increased	11		Harm reduction
Syringe exchange programs	6	Vending machines in Nevada	Harm reduction
Expand treatment workforce	6	University training, specific to SUD	OUD treatment

Description	States (n**)	Examples	Domain/Subdomain
Support the location (finding) of SUD treatment	4	RI requires health department to maintain real-time database of open inpatient and outpatient slots.	OUD treatment
Expand medication for opioid use disorder treatment	8	WI changed methadone clinic regulations to align with federal regulations	OUD treatment
Enhance quality of care initiatives	12	Several states added requirement for discharge planning	OUD treatment
Improve insurance coverage for SUD care	10	VA added criteria for Medicaid managed care to cover appropriate levels of care	OUD treatment
Expand recovery support services	8	Missouri added credentialing requirements for peer support specialists.	OUD treatment
Expand role of law enforcement in SUD care	6	TN adds program to train police to better cope with SUD crises. DE added program to permit treatment in lieu of arrest.	OUD treatment/Social issues
Expand jail diversion programs	9	Maryland and Georgia set aside \$13 million in funding to support.	OUD treatment/Social issues
Expand SUD treatment in jails and prisons	7		OUD treatment/Social issues
Initiatives to connect former inmates to treatment and recovery resources upon release from incarceration	7	Maryland has program to offer post-release treatment, housing, education, and employment assistance.	OUD treatment/Social issues

*The National Center on Addiction and Substance Abuse (CASA), *Ending the Opioid Crisis: A Practical Guide for State Policymakers*, October 2017, available at <http://www.centeronaddiction.org>.

** At least this number of individual states have such laws or policies specific to the opioid crisis.

Key Informants

The goals of the key informant interviews were to supplement the environmental scan and identify gap areas for future measures. A convenience sample was used for this data gathering exercise based on staff knowledge of the field and CMS and TEP input. Ultimately, eight informants were selected with the aim of obtaining more information in the following areas: health services research and economics, rural issues, patient and family experience, measure development, pharmaceuticals, Medicaid, and dentistry. See the table summarizing the key informants for more information (Appendix C).

Appendix C: Key Informant Interview Guide

Thank you for participating in this “key informant” interview for the National Quality Forum’s Opioid and Opioid Use Disorder Technical Expert Panel. The TEP is focused on identifying quality measures, measure concepts, and future directions for quality measurement development related to the opioid epidemic now faced by the U.S. You have been given a preview of the questions, so we will jump right in and have you address them as thoroughly as you can over the next hour. Our intent is to record and use your comments to inform our 30-member TEP, and to inform staff’s creation of a written and public environmental scan and overall TEP report documents. In those documents we may quote you, and thus today we will be recording our conversation, so please consider your remarks as “on the record”, unless you express to us otherwise. We want to give you proper attribution, but only with your full consent to do so. Does that sound OK?

Before we get into our questions, please let us know if there is anyone joining you.

Very good, let’s begin:

1. What concepts (i.e., ideas, theories, principles, contexts) do you regard as contemporary and essential to advancing quality measurement related to the opioid epidemic?
 - a. Concepts in the pain control domain?
 - b. Concepts in the substance use disorder domain?
 - c. Overriding health and healthcare concepts of particular importance?
2. What is your current knowledge of quality measurement tools germane to the opioid epidemic, and where do you think major “gaps” exist regarding that tool set as you know it?
 - a. Please first characterize for us your current knowledge of opioid-related quality measures?
 - b. Pick 1 to 3 major gaps you see as high priority?
 - c. Any specific databases/archives that you think we must check for existing or pipeline measures?
3. What peer-reviewed and grey scholarly or technical literature must the TEP consider?
 - a. Select up to three peer-reviewed pieces and suggest why you think they are of supreme importance.
 - b. Selection up to three grey literature pieces similarly.
4. Any other comments, questions, or words of inspiration you wish to offer to NQF’s Opioid and Opioid Use Disorder TEP?

Key Informant	Current Background	Expertise
Kyle Null, PharmD, PhD	Senior Director, Outcomes Research and Data Science at Meridian, Mississippi Pharmaceuticals	Pharmacist and health services research using administrative claims data, healthcare payment systems, bundled and prospective payment systems, quality and performance-based payment systems
Tami Mark, PhD	Senior Director, Behavioral Health Financing and Quality Measurement	Behavioral health treatment systems through research, data analytics, and policy development
Brendan Saloner, PhD	Assistant Professor at Johns Hopkins University Bloomberg School of Public Health	Health policy management, intersection of health and social policy with respect to health insurance use in promotion of access to care, financial protection, and wellness
Melissa Azur, PhD*	Associate Director at Mathematica	Mental health services and policies, development of quality behavioral health measures, quality measurement
Mr. Justin Riley, MBA	President and CEO of Young People in Recovery (YPR)	Patient advocate, long-term recovery survivor, White House Champion of Change award recipient, member of the National Advisory Council for the Substance Abuse Mental Health Administration and the Executive Committee for the Coalition to Stop Opioid Overdose
Omar Abubaker, DMD, PhD	Professor and S. Elmer Bear Chair at VCU College of Dentistry	Patient advocate, experienced loss of family member to opioid addiction, graduate of program on addiction, clinician and educator at VCU College of Dentistry
Tripp Logan, PharmD	Vice President/Pharmacy Consultant at MedHere Today	Rural health experience, community pharmacy owner, part of the quality metrics expert panel at the Pharmacy Quality Alliance (PQA), strong background in measure development through PQA for eight years

*Drs. Deborah Garnick and Cindy Thomas of The Heller School for Social Policy and Management at Brandeis University assisted Dr. Azur in her responses.

Appendix D: Measure Inventory

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
1		Activity counseling for back pain	Percentage of patients 18 to 65 years of age who were counseled to remain active and exercise or were referred to physical therapy	Process	Pain Management	Alternatives to Opioids
2		Acute Medication Prescribed for Cluster Headache	Percentage of patients age 18 years old and older with a diagnosis of cluster headache (CH) who were prescribed a guideline recommended acute medication for cluster headache within the 12-month measurement period.	Process	Pain Management	Alternatives to Opioids
3		Adult smoking cessation advice/counseling	Heart failure patients with a history of smoking cigarettes, who are given smoking cessation advice or counseling during hospital stay. For purposes of this measure, a smoker is defined as someone who has smoked cigarettes anytime during the year prior to hospital arrival.	Process	ODU Treatment	Psychiatric or Dependence Comorbidity
4	Endorsed	Alcohol & Other Drug Use Disorder Treatment at Discharge	This rate describes only those who receive a prescription for FDA-approved medications for alcohol or drug use disorder OR a referral for addictions treatment.	Process	ODU Treatment	ODU Treatment Initiation
5		Alcohol and Drug Use Assessing Status After Discharge	Discharged patients who received a diagnosis of alcohol or drug disorder during their inpatient stay, who are contacted between 7 and 30 days after hospital discharge and follow-up information regarding their alcohol or drug use status post discharge is collected.	Process	ODU Treatment	ODU Treatment Continuity
6		Alcohol Problem Use Assessment & Brief Intervention for Home-Based Primary Care and Palliative Care Patients	Percentage of newly enrolled and active home-based primary care and palliative care patients who were assessed for a problem with alcohol use at enrollment AND if positive, have a brief intervention for problematic alcohol use documented on the date of the positive assessment.	Process	ODU Treatment	Psychiatric or Dependence Comorbidity
7		Alcohol Screening and Brief Intervention (ASBI) in the ER	Percentage of patients aged 15 to 34 seen in the ER for injury who were screened for hazardous alcohol use AND provided a brief intervention within 7 days of the ER visit if screened positive.	Process	ODU Treatment	Psychiatric or Dependence Comorbidity
8	Endorsed	Alcohol Use Brief Intervention Provided or Offered	<p>The measure is reported as an overall rate which includes all hospitalized patients 18 years of age and older to whom a brief intervention was provided, or offered and refused, and a second rate, a subset of the first, which includes only those patients who received a brief intervention. The Provided or Offered rate (SUB-2), describes patients who screened positive for unhealthy alcohol use who received or refused a brief intervention during the hospital stay. The Alcohol Use Brief Intervention (SUB-2a) rate describes only those who received the brief intervention during the hospital stay. Those who refused are not included.</p> <p>These measures are intended to be used as part of a set of 4 linked measures addressing Substance Use (SUB-1 Alcohol Use Screening ; SUB-2 Alcohol Use Brief Intervention Provided or Offered; SUB-3 Alcohol and Other Drug Use Disorder Treatment Provided or Offered at Discharge; SUB-4 Alcohol and Drug Use: Assessing Status after Discharge).</p>	Process	ODU Treatment	Psychiatric or Dependence Comorbidity
9		All cause inpatient, residential re-admission	This measure is used to assess the rate of all-cause unplanned readmissions, 90 days following an initial episode of residential/inpatient SUD treatment and assesses the clinician's management of the patient's entire medical condition.	Process	ODU Treatment	ODU Treatment Continuity
10		Ambulatory Post-Discharge Patient Follow-Up	Percentage of patients, regardless of age, who received anesthesia services in an ambulatory setting whose post-discharge status was assessed within 72 hours of discharge	Process	Pain Management	Appropriate Opioid Analgesic Prescribing

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
11		Annual Monitoring for Individuals on Chronic Opioid Therapy	The proportion of patients age 18 years and older who are continuously enrolled in a Qualified Health Plan product and on chronic opioid therapy who have not received a drug test at least once during the measurement year.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
12		Appropriate controlled substance prescribing (definitive diagnosis(es)) via adherence to Controlled Substance Agreements (CSA) or (OA's) with corrective action taken for pain and/or substance use disorder patients when violations occur.	<p>1. Successful Reporting:</p> <p>a. Documentation of definitive pathology (e.g., imaging, surgical report, serology, provider referral for addiction/substance use disorder, etc.) to warrant chronic pain and/or buprenorphine/naloxone medication chronically.</p> <p>b. Provider must document signing of a Controlled Substance (CSA) or Opiate Agreement (OA) if more than two (2) Schedule II controlled substance prescriptions are provided to a patient in a 12-month period. Understandably, prescriptions may occur in the prior reporting year as well as in the current reporting year.</p> <p>c. For all patients violating existing CSA/OA, such violations are documented with correlative adjustments in treatment (e.g.: shorter duration prescriptions (2 week to 4 week), increased frequency of urine drug screens (quarterly to monthly), random pill counts, more frequent visits, etc.).</p> <p>2. Numerator & Denominator. Numerator data are patients aged 18 and above with documented definitive pathology of ICD data below. Denominator data are all patients aged 18 and above with any combination of the ICD and HCPCS data defined in this section 3, below.</p> <p>3. Measure explanation: Chronic Pain medication prescribed (prescribed for greater than one week or more than twice a year) only after a diagnosis and medical or surgical plan has been implemented. CSA or OA followed and, if actionable violation (i.e.: Urine Drug Screen inappropriate, pill counts off, multiple providers prescribing, polypharmacy, etc.) corrective action taken (i.e.: probation, escalated use of Urine Drug Screens, shorter prescriptions intervals, termination of controlled prescribing or similar actions) as result of the CSA/OA violation.</p>	Outcome	Pain Management	Appropriate Opioid Analgesic Prescribing
13		Appropriate Monitoring for Adverse Events of Opioid and Psychiatric Medications	<p>This measure assesses whether established guidelines to monitor for common ADEs of opioid and psychiatric medications that are administered to patients during inpatient psychiatric facility admissions are being followed.</p> <p>The performance period for the measure is one year.</p>	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
14		Appropriate Monitoring of patients receiving an Opioid via an IV Patient Controlled Analgesia Device	Patients receiving intravenous opioids via patient controlled analgesia who receive appropriate monitoring of their respiratory status (respiratory rate and pulse oximetry) and level of sedation	Process	Pain Management	Appropriate Opioid Analgesic Prescribing

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
15		Appropriate Prescribing for First Fill of Opioids	The percentage of adults, 18 and older, who fill an initial prescription for opioid medications that does not comply with at least one of five separate measure components derived from the 2016 Centers for Disease Control (CDC) Guideline for prescribing of opioid medications that are measurable in secondary administrative claims data. Lower is better on this measure.	Composite	Pain Management	Appropriate Opioid Analgesic Prescribing
16		Assessment and management of chronic pain: percentage of patients with chronic pain diagnosis with documentation of a pain assessment completed at initial visit using a standardized tool	This measure is used to assess the percentage of patients age 16 years and older with chronic pain diagnosis with documentation of a pain assessment completed at initial visit using a standardized tool that addresses pain intensity, location, pattern, mechanism of pain, current functional status and follow-up plan	Process	Pain Management	Pain Assessment
17		Avoid Certain Opioid Analgesics in the Elderly © ActiveHealth	Percentage of patients 65 years or older who were prescribed certain opioid analgesics	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
18		Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions	Percentage of Adult Patients Who Were Prescribed an Opiate Who Were Not Prescribed a Long-Acting (LA) or Extended-Release (ER) Formulation	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
19		Avoidance of Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain	Percentage of Adult Patients Who Were Prescribed an Opiate for Whom the Prescription Duration Was Not Greater than 3 days for Acute Pain	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
20		Avoidance of Opiates for Low Back Pain or Migraines	Percentage of Patients with Low Back Pain and/or Migraines Who Were Not Prescribed an Opiate	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
21		Avoiding Use of CNS Depressants in Patients on Long-Term Opioids	The percentage of patients on long-term opioid prescriptions without a concurrent prescription for an CNS depressant	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
22		Back Pain: Initial Visit	Percentage of patients at least 18 years of age and younger than 80 with a diagnosis of back pain who have medical record documentation of all of the following on the date of the initial visit to the physician: 1. Pain assessment 2. Functional status 3. Patient history, including notation of presence or absence of “red flags” 4. Assessment of prior treatment and response, and 5. Employment status	Process	Pain Management	Pain Assessment
23		Bipolar Disorder and Major Depression: Appraisal for Alcohol or Chemical Substance Use	Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use	Process	OUD Treatment	OUD Screening
24	Endorsed	CAHPS Hospice Survey: Getting Help for Symptoms	Multi-item measure P1: Did your family member get as much help with pain as he or she needed P2: How often did your family member get the help he or she needed for trouble breathing P3: How often did your family member get the help he or she needed for trouble with constipation P4: How often did your family member receive the help he or she needed from the hospice team for feelings of anxiety or sadness	Outcome: PRO-PM	Pain Management	Pain Assessment

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
25		Care for Older Adults Pain Assessment	Percent of plan members who had a pain screening or pain management plan at least once during the year. (This information about pain screening or pain management is collected for Medicare Special Needs Plans only. These plans are a type of Medicare Advantage Plan designed for certain types of people with Medicare. Some Special Needs Plans are for people with certain chronic diseases and conditions, some are for people who have both Medicare and Medicaid, and some are for people who live in an institution such as a nursing home.)	Process	Pain Management	Pain Assessment
26		Care for Older Adults: Advance Care Planning, Functional Status Assessment, Pain Screening	Care for Older Adults: The percentage of adults 65 years and older who received the following during the measurement year: <ul style="list-style-type: none"> • Advance Care Planning • Functional Status Assessment • Pain Screening 	Outcome	Pain Management	QoL/Function
27		Change in Patient Reported Pain and Functional Status Following Spinal Cord Stimulator Implantation	Measurement of the change in patient reported quality of life following spinal cord stimulator implantation for failed back surgery syndrome. Quality of life measurement on standardized scale includes pain, mobility, analgesic medication use, psychological well-being and activities of daily living.	Outcome: PRO-PM	Pain Management	Pain Score Change
28		Chronic Opioid Therapy Follow up Evaluation	All patients 18 and older prescribed opiates for longer than six weeks duration who had a follow-up evaluation conducted at least every three months during COT documented in the medical record.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
29	Endorsed	Comfortable Dying: Pain Brought to a Comfortable Level Within 48 Hours of Initial Assessment	Number of patients who report being uncomfortable because of pain at the initial assessment (after admission to hospice services) who report pain was brought to a comfortable level within 48 hours.	Intermediate Outcome	Pain Management	Time to Pain Management
30		Communication about Pain During the Hospital Stay	The following questions (or a subset of questions) would replace the current Pain Management measure in the HCAHPS Survey with a new measure(s). The following items were tested in early 2016. CMS is currently analyzing the results, as well as discussing these potential new pain management items with focus groups and hospital staff. Multi-item measure (composite): HP1: During this hospital stay, did you have any pain HP2: During this hospital stay, how often did hospital staff talk with you about how much pain you had HP3: During this hospital stay, how often did hospital staff talk with you about how to treat your pain	Outcome: PRO-PM	Pain Management	Pain Assessment
31		Communication about Treating Pain Post-Discharge	The following questions (or a subset of questions) would replace the current Pain Management measure in the HCAHPS Survey with a new measure(s). The following items were tested in early 2016. CMS is currently analyzing the results, as well as discussing these potential new pain management items with focus groups and hospital staff. Multi-item measure (composite): DP1: Before you left the hospital, did someone talk with you about how to treat pain after you got home DP2: Before you left the hospital, did hospital staff give you a prescription for medicine to treat pain DP3: Before giving you the prescription for pain medicine, did hospital staff describe possible side effects in a way you could understand	Outcome	Pain Management	Pain Assessment

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
32		Concomitant Chronic Opioid Analgesic Therapy and Benzodiazepines Prescribing Rate	The number of patients prescribed an elevated dose (≥ 50 MME per day) of chronic opioid analgesic therapy (COAT) who have greater than 7 days of overlapping benzodiazepine therapy in the measurement year. The overlapping benzodiazepine therapy days must be from one prescription in order to meet the inclusion criteria.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
33	Endorsed	Concurrent Use of Opioids and Benzodiazepines (COB)	The percentage of individuals 18 years and older with concurrent use of prescription opioids and benzodiazepines during the measurement year. A lower rate indicates better performance.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
34		Consideration of Non Pharmacologic Interventions	All patients 18 and older prescribed opiates for longer than six weeks duration with whom the clinician discussed nonpharmacologic interventions (e.g. graded exercise, cognitive/behavioral therapy, activity coaching at least once during COT documented in the medical record.	Process	Pain Management	Alternatives to Opioids
35		Constipation assessment following narcotic prescription in patients diagnosed with cancer	Percentage of patients for whom constipation was assessed at the time of narcotic prescription or the following visit	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
36		Continuity of Care after Detox	This measure is defined as the percent of individuals who receive a detoxification service and received another substance abuse service (other than detoxification or crisis care) within 14 days of discharge from detoxification.	Access	OUD Treatment	OUD Treatment Continuity
37	Endorsed	Continuity of care after inpatient or residential treatment for substance use disorder (SUD)	Percentage of discharges from an inpatient or residential treatment for substance use disorder (SUD) for Medicaid beneficiaries, ages 18 to 64, which was followed by a treatment service for SUD. SUD treatment includes having an outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth encounter, or filling a prescription or being administered or ordered a medication for SUD. (After an inpatient discharge only, residential treatment also counts as continuity of care.) Two rates are reported, continuity within 7 and 14 days after discharge.	Process	OUD Treatment	OUD Treatment Continuity
38	Endorsed	Continuity of Care for Medicaid Beneficiaries after Detoxification (Detox) From Alcohol and/or Drugs	Percentage of discharges from a detoxification episode for adult Medicaid Beneficiaries, age 18-64, that was followed by a treatment service for substance use disorder (including the prescription or receipt of a medication to treat a substance use disorder (pharmacotherapy) within 7 or 14 days after discharge. This measure is reported across all detoxification settings.	Process	OUD Treatment	OUD Treatment Continuity
39		Continuity of Pharmacotherapy for Alcohol Use Disorder	Percentage of adults 18-64 years of age with pharmacotherapy for alcohol use disorder (AUD) who have at least 180 days of treatment and a Proportion of Days Covered (PDC) of at least 0.8	Process	OUD Treatment	Psychiatric or Dependence Comorbidity
40	Endorsed	Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)	Percentage of adults aged 18 years and older with pharmacotherapy for opioid use disorder (OUD) who have at least 180 days of continuous treatment	Process	OUD Treatment	OUD Treatment Continuity
41		Counseling on physical activity in older adults - a. Discussing Physical Activity, b. Advising Physical Activity	Discussing Physical Activity: Percentage patients 65 years of age and older who reported: discussing their level of exercise or physical activity with a doctor or other health provider in the last 12 months. Advising Physical Activity: Percentage patients 65 years of age and older who reported receiving advice to start, increase, or maintain their level of exercise or physical activity from a doctor or other health provider in the last 12 months.	Process	Pain Management	Alternatives to Opioids

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
42		Counseling Regarding Pharmacological Treatment for Opioid Dependence	This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counseled regarding psychosocial and pharmacologic treatment options for opioid addiction within the 12 month reporting period.	Process	OUD Treatment	OUD Treatment Initiation
43		Counseling Regarding Psychosocial and Pharmacological Treatment Options for Alcohol Dependence	This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of current alcohol dependence who were counseled regarding psychosocial AND pharmacologic treatment options for alcohol dependence within the 12 month reporting period.	Process	OUD Treatment	Psychiatric or Dependence Comorbidity
44		Depression and Anxiety Assessment Prior to Spine-Related Therapies	Percentage of patients aged 18 years and older with documentation of depression and/or anxiety assessment through discussion with the patient including the use of a standardized assessment tool prior to index therapy(-ies) for treatment of spine-related pain symptoms.	Process	OUD Treatment	Psychiatric or Dependence Comorbidity
45		Discharge Prescription of Naloxone after Opioid Poisoning or Overdose	Percentage of Opioid Poisoning or Overdose Patients Presenting to An Acute Care Facility Who Were Prescribed Naloxone at Discharge	Process	Harm Reduction	Opioid Reversal Drug Prescription
46		Documentation of Signed Opioid Treatment Agreement	All patients 18 and older prescribed opiates for longer than six weeks duration who signed an opioid treatment agreement at least once during COT documented in the medical record.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
47		Emergency Department Use Due to Opioid Overdose	This is a claims-based measure that captures the rate of emergency department visits for opioid overdose events using ICD-9 or ICD-10 diagnosis codes. Events are measured per 1,000 person-years among Medicare beneficiaries greater than 18 years of age residing in the geography being measured. The measure is designed for use at both the county and state levels.	Outcome	Harm Reduction	Overdose
48		Emergent care for improper medication administration, medication side effects	Percentage of home health quality episodes of care during which the patient required emergency medical treatment from a hospital emergency department related to improper medication administration or medication side effects.	Outcome	Harm Reduction	Overdose
49		Evaluation of High Risk Pain Medications for MME	Percentage of patients aged 18 years and older prescribed and actively taking one or more high risk pain medications and evaluated for clinical appropriateness of morphine milligram equivalents (MME)	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
50		Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with hip, leg or ankle (lower extremity except knee) injury.	The proportion of patients failing to achieve an MCID of two (2) points or more improvement in the NPRS change score for patients with hip, leg, or ankle injuries treated during the observation period will be reported. Additionally, a risk-adjusted MCID proportional difference will be determined by calculating the difference between the risk model predicted and observed MCID proportion will reported for each physical therapist or physical therapy group. The risk adjustment will be calculated using a logistic regression model using: LEFS score, baseline pain score, age, sex, payer, and symptom duration (time from surgery or injury to baseline physical therapy visit). These measures will serve as a physical or occupational therapy performance measure at the eligible physical or occupational therapist or physical or occupational therapy group level.	Outcome: PRO-PM	Pain Management	Pain Score Change

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
51		Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in revalidation patients with knee injury pain.	<p>The proportion of patients failing to achieve MCID of two (2) points or more improvement in the NPRS change score for patients with knee injuries treated during the observation period will be reported.</p> <p>Additionally, a risk-adjusted MCID proportional difference will be determined by calculating the difference between the risk model predicted and observed MCID proportion will reported for each physical therapist or physical therapy group. The risk adjustment will be calculated using a logistic regression model using: baseline KOS score, baseline pain score, age, sex, payer, and symptom duration (time from surgery or injury to baseline physical therapy visit).</p> <p>These measures will serve as a physical or occupational therapy performance measure at the eligible physical or occupational therapist or physical or occupational therapy group level.</p>	Outcome: PRO-PM	Pain Management	Pain Score Change
52		Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in revalidation patients with low back pain.	<p>The proportion of patients failing to achieve an MCID of two (2) points or more improvement in the NPRS change score for patients with low back pain treated during the observation period will be reported.</p> <p>Additionally, a risk-adjusted MCID proportional difference will be determined by calculating the difference between the risk model predicted and observed MCID proportion will reported for each physical therapist or physical therapy group. The risk adjustment will be calculated using a logistic regression model using: baseline MDQ score, baseline pain score, age, sex, payer, and symptom duration (time from surgery or injury to baseline physical therapy visit).</p> <p>These measures will serve as a physical or occupational therapy performance measure at the eligible physical or occupational therapist or physical or occupational therapy group level.</p>	Outcome: PRO-PM	Pain Management	Pain Score Change
53		Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with arm, shoulder, or hand injury.	<p>The proportion of patients failing to achieve an MCID of two (2) points or more improvement in the NPRS change score for patients with arm, shoulder, or hand injury treated during the observation period will be reported.</p> <p>Additionally, a risk-adjusted MCID proportional difference will be determined by calculating the difference between the risk model predicted and observed MCID proportion will reported for each physical therapist or physical therapy group. The risk adjustment will be calculated using a logistic regression model using: baseline DASH score, baseline pain score, age, sex, payer, and symptom duration (time from surgery or injury to baseline physical therapy visit).</p> <p>These measures will serve as a physical or occupational therapy performance measure at the eligible physical or occupational therapist or physical or occupational therapy group level.</p>	Outcome: PRO-PM	Pain Management	Pain Score Change

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
54		Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with arm, shoulder, or hand injury.	<p>The proportion of patients failing to achieve an MCID of two (2) points or more improvement in the NPRS change score for patients with arm, shoulder, or hand injury treated during the observation period will be reported.</p> <p>Additionally, a risk-adjusted MCID proportional difference will be determined by calculating the difference between the risk model predicted and observed MCID proportion will reported for each physical therapist or physical therapy group. The risk adjustment will be calculated using a logistic regression model using: baseline DASH score, baseline pain score, age, sex, payer, and symptom duration (time from surgery or injury to baseline physical therapy visit).</p> <p>These measures will serve as a physical or occupational therapy performance measure at the eligible physical or occupational therapist or physical or occupational therapy group level.</p>	Outcome: PRO-PM	Pain Management	Pain Score Change
55		Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with neck pain/injury.	<p>The proportion of patients failing to achieve an MCID of two (2) points or more improvement in the NPRS change score for patients with neck pain/injury treated during the observation period will be reported.</p> <p>Additionally, a risk-adjusted MCID proportional difference will be determined by calculating the difference between the risk model predicted and observed MCID proportion will reported for each physical therapist or physical therapy group. The risk adjustment will be calculated using a logistic regression model using: baseline NDI score, baseline pain score, age, sex, payer, and symptom duration (time from surgery or injury to baseline physical therapy visit).</p> <p>These measures will serve as a physical or occupational therapy performance measure at the eligible physical or occupational therapist or physical or occupational therapy group level.</p>	Outcome: PRO-PM	Pain Management	Pain Score Change
56		Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in knee rehabilitation of patients with knee injury measured via their validated Knee Outcome Survey (KOS) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.	<p>The proportion of patients failing to achieve an MCID of ten (10) points or more improvement in the KOS change score for patients with knee injury patients treated during the observation period will be reported.</p> <p>Additionally, a risk-adjusted MCID proportional difference will be determined by calculating the difference between the risk model predicted and observed MCID proportion will reported for each physical therapist or physical therapy group. The risk adjustment will be calculated using a logistic regression model using: baseline KOS score, baseline pain score, age, sex, payer, and symptom duration (time from surgery or injury to baseline physical therapy visit).</p> <p>These measures will serve as a PT/OT performance measure at the eligible PT/OT or PT/OT group level.</p>	Outcome: PRO-PM	Pain Management	Pain Score Change

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
57	Endorsed	Follow-Up After Hospitalization for Mental Illness	The percentage of discharges for patients 6 years of age and older who were hospitalized for treatment of selected mental illness diagnoses and who had a follow-up visit with a mental health practitioner. Two rates are reported: - The percentage of discharges for which the patient received follow-up within 30 days of discharge - The percentage of discharges for which the patient received follow-up within 7 days of discharge.	Process	ODU Treatment	Psychiatric and/or Other Illness Comorbidity
58	Endorsed	HBIPS-1 Admission Screening for Violence Risk, Substance Use, Psychological Trauma History and Patient Strengths Completed	The proportion of patients, age greater than and equal to 1 year, admitted to a hospital-based inpatient psychiatric setting who are screened within the first three days of hospitalization for all of the following: risk of violence to self or others, substance use, psychological trauma history and patient strengths.	Process	ODU Treatment	ODU Screening
59		HBIPS-6 Post discharge continuing care plan created	The proportion of patients discharged from a hospital-based inpatient psychiatric setting with a post discharge continuing care plan created. This measure is a part of a set of seven nationally implemented measures that address hospital-based inpatient psychiatric services (HBIPS-1: Admission Screening for Violence Risk, Substance Use, Psychological Trauma History and Patient Strengths completed, HBIPS-2: Physical Restraint, HBIPS-3: Seclusion, HBIPS-4: Multiple Antipsychotic Medications at Discharge, HBIPS-5: Multiple Antipsychotic Medications at Discharge with Appropriate Justification and HBIPS-7: Post Discharge Continuing Care Plan Transmitted) that are used in The Joint Commission's accreditation process. Note that this is a paired measure with HBIPS-7 (Post Discharge Continuing Care Plan Transmitted).	Process	ODU Treatment	Psychiatric and/or Other Illness Comorbidity
60		HBIPS-7 Post discharge continuing care plan transmitted to next level of care provider upon discharge	The proportion of patients discharged from a hospital-based inpatient psychiatric setting with a complete post discharge continuing care plan, all the components of which are transmitted to the next level of care provider upon discharge. This measure is a part of a set of seven nationally implemented measures that address hospital-based inpatient psychiatric services (HBIPS-1: Admission Screening for Violence Risk, Substance Use, Psychological Trauma History and Patient Strengths completed, HBIPS-2: Physical Restraint, HBIPS-3: Seclusion, HBIPS-4: Multiple Antipsychotic Medications at Discharge, HBIPS-5: Multiple Antipsychotic Medications at Discharge with Appropriate Justification and HBIPS-6: Post Discharge Continuing Care Plan Created) that are used in The Joint Commission's accreditation process. Note that this is a paired measure with HBIPS-6 (Post Discharge Continuing Care Plan Created).	Process	ODU Treatment	Psychiatric and/or Other Illness Comorbidity

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
61	Endorsed	HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) Survey	HCAHPS (NQF #0166) is a 32-item survey instrument that produces 11 publicly reported measures: 7 multi-item measures (communication with doctors, communication with nurses, responsiveness of hospital staff, pain control, communication about medicines, discharge information and care transition); and 4 single-item measures (cleanliness of the hospital environment, quietness of the hospital environment, overall rating of the hospital, and recommendation of hospital). Please note: Beginning with patients discharged in January 2018, the three original Pain Management items were removed from the HCAHPS Survey and replaced by three new items that will comprise the new Communication About Pain measure. The original Pain Management measure will be publicly reported on the Hospital Compare Web site until December 2018. The new Communication About Pain measure will be publicly reported beginning in October 2020.	Outcome	Pain Management	Pain Assessment
62	Endorsed	Health literacy measure derived from the health literacy domain of the C-CAT	0-100 measure of health literacy related to patient-centered communication, derived from items on the staff and patient surveys of the Communication Climate Assessment Toolkit	Outcome	Social Issues	Health Literacy
63		Heel Pain Treatment Outcomes for Adults	DESCRIPTION: Percentage of patients aged 18 years and older with a diagnosis of heel pain who had two or more encounters in the past year.	Outcome: PRO-PM	Pain Management	Pain Score Change
64		Heel Pain Treatment Outcomes for Pediatric Patients	Percentage of patients aged 6 to 18 years with a diagnosis of heel pain who experience a decrease in heel pain.	Outcome: PRO-PM	Pain Management	Pain Score Change
65		High-Dose Chronic Opioid Analgesic Therapy Prescribing Rate	The percentage of enrollees prescribed chronic opioid analgesic therapy (COAT) that met or exceeded the daily dose recommendation upper limit of 90 Morphine Milligram Equivalence (MME) per day in the measurement year.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
66		History and Physical Examination for Opioid Users	All patients 18 and older prescribed opiates for longer than six weeks duration who had a history and physical examination* conducted at least once during COT documented in the medical record.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
67	Endorsed	Hospice and Palliative Care Composite Process Measure—Comprehensive Assessment at Admission	The Hospice Comprehensive Assessment Measure assesses the percentage of hospice stays in which patients who received a comprehensive patient assessment at hospice admission. The measure focuses on hospice patients age 18 years and older. A total of seven individual NQF endorsed component quality will provide the source data for this comprehensive assessment measure, including NQF #1634, NQF #1637, NQF #1639, NQF #1638, NQF #1617, NQF #1641, and NQF #1647. These seven measures are currently implemented in the CMS HQR. These seven measures focus on care processes around hospice admission that are clinically recommended or required in the hospice Conditions of Participation, including patient preferences regarding life-sustaining treatments, care for spiritual and existential concerns, and management of pain, dyspnea, and bowels.	Composite	Pain Management	Pain Assessment

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
68		Hospital Harm – Opioid-Related Adverse Events	This electronic clinical quality measure (eCQM) assesses the proportion of inpatient admissions for patients age 18 years and older who suffer the harm of receiving an excess of hospital-administered opioids, defined as receiving a narcotic antagonist (naloxone). In the first 24 hours of the hospitalization, a hospital-administered opioid must be documented prior to receiving naloxone to be considered part of the numerator.	Outcome	Harm Reduction	Overdose
69		Hospital Harm Performance Measure: Opioid Related Adverse Respiratory Events	This measure will assess opioid related adverse respiratory events (ORARE) in the hospital setting. The goal for this measure is to assess the rate at which naloxone is given for opioid related adverse respiratory events that occur in the hospital setting, using a valid method that reliably allows comparison across hospitals.	Outcome	Harm Reduction	Overdose
70		Hospital-level risk-standardized Opioid extended use rate following THA and/or TKA (Opioid extended use)	This measure estimates the proportion of individuals without cancer who had any (1) opioid prescription filed between 90- and 180-days post TKA and/or THA. The target population is patients who are 65 years and older, are enrolled in fee-for-service (FFS) Medicare, and discharged from BWH and other PHS acute-care hospitals following THA/TKA.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
71		Identification of Major Co-Morbid Medical Conditions	Percentage of patients 18 years or older undergoing an elective surgical procedure who received general or spinal anesthesia AND who has documentation of a significant co-morbid condition(s) in their medical record within 30 days of operation date.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
72		Identification of Opioid Use Disorder among Patients Admitted to Inpatient Psychiatric Facilities	The measure assesses the percentage of patients admitted to an inpatient psychiatric facility who were screened and evaluated for opioid use disorder. The performance period for the measure is one year.	Process	OUD Treatment	OUD Screening
73		Immediate Adult Post-Operative Pain Management	The percentage of patients 18 or older admitted to the PACU after an anesthetic with a maximum pain score <7/10 prior to anesthesia end time.	Outcome	Pain Management	Pain Score Change
74	Endorsed	Improvement in Pain Interfering with Activity	Percentage of home health episodes of care during which the patient's frequency of pain when moving around improved.	Outcome	Pain Management	Pain Score Change
75		Improving or Maintaining Mental Health	Percent of all plan members whose mental health was the same or better than expected after two years.	Outcome	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
76		Index Opioid Prescription Prescribing Rate	The prescribing rate of index opioid prescriptions to enrollees during the measurement year.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
77		Initial Opioid Prescribing at High Dosage	The percentage of individuals ≥18 years of age with ≥1 initial opioid prescriptions with an average daily morphine milligram equivalent (MME) of ≥50. (Excludes patients in hospice care and those with cancer.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
78		Initial Opioid Prescribing for Long Duration	The percentage of individuals ≥18 years of age with ≥1 initial opioid prescriptions for >7 cumulative days' supply.(Excludes patients in hospice care and those with cancer	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
79		Initial Opioid Prescribing for Long-Acting or Extended-Release High Dosage	The percentage of individuals ≥18 years of age with ≥1 initial opioid prescriptions for long-acting or extended-release opioids.(Excludes patients in hospice care and those with cancer	Process	Pain Management	Appropriate Opioid Analgesic Prescribing

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
80		Initial opioid prescription compliant with CDC recommendations	Composite score indicating compliance with five measurable CDC opioid prescribing guidelines. The denominator includes new opioid prescriptions in the measurement year. The numerator includes new opioid prescriptions that are compliant on all 5 CDC indicators. Higher is better on this measure.	Composite	Pain Management	Appropriate Opioid Analgesic Prescribing
81	Endorsed	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment	<p>This measure assesses the degree to which the organization initiates and engages members identified with a need for alcohol and other drug (AOD) abuse and dependence services and the degree to which members initiate and continue treatment once the need has been identified. Two rates are reported:</p> <ul style="list-style-type: none"> • Initiation of AOD Treatment. The percentage of adolescent and adult members with a new episode of AOD abuse or dependence who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth or medication assisted treatment (MAT) within 14 days of the diagnosis. • Engagement of AOD Treatment. The percentage of adolescent and adult members with a new episode of AOD abuse or dependence who initiated treatment and who had two or more additional AOD services or MAT within 34 days of the initiation visit. 	Process	OUD Treatment	OUD Treatment Initiation
82	Endorsed	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET-AD)	<p>Percentage of Medicaid beneficiaries age 18 and older with a new episode of alcohol or other drug (AOD) abuse or dependence who received the following:</p> <p>Initiation of AOD Treatment. Percentage of beneficiaries who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth, or medication assisted treatment (MAT) within 14 days of the diagnosis</p> <p>Engagement of AOD Treatment. Percentage of beneficiaries who initiate treatment and who had two or more additional AOD services or MAT within 34 days of the initiation visit</p>	Process	OUD Treatment	OUD Treatment Initiation
83	Endorsed	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET-HH)	<p>Percentage of Health Home enrollees age 13 and older with a new episode of alcohol or other drug (AOD) abuse or dependence who received the following:</p> <p>Initiation of AOD Treatment. Percentage of beneficiaries who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth, or medication assisted treatment (MAT) within 14 days of the diagnosis</p> <p>Engagement of AOD Treatment. Percentage of beneficiaries who initiate treatment and who had two or more additional AOD services or MAT within 34 days of the initiation visit</p>	Process	OUD Treatment	OUD Treatment Initiation

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
84		Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	The percentage of adolescent and adult members with a new episode of alcohol or other drug (AOD) dependence who received the following: a. Initiation of AOD Treatment. The percentage of members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis. b. Engagement of AOD Treatment. The percentage of members who initiated treatment and who had two or more additional services with a diagnosis of AOD within 30 days of the initiation visit.	Process	ODU Treatment	ODU Treatment Initiation
85	Endorsed	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (eCQM)	Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported a. Percentage of patients who initiated treatment within 14 days of the diagnosis b. Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit	Process	ODU Treatment	ODU Treatment Initiation
86		Inpatient Assessment of Depression Symptoms	The purpose of this measure is to improve the monitoring of the severity of depression as a part of the treatment care plan by implementing the PHQ-9 in the inpatient setting. This process measure will serve as a complementary patient-reported outcome performance measure (PRO-PM) that would evaluate risk-adjusted symptom improvement in patients admitted to inpatient facilities.	Process	ODU Treatment	Psychiatric and/or Other Illness Comorbidity
87		Intimate Partner (Domestic) Violence Screening	Percentage of female patients aged 15-40 years old who were screened for intimate partner (domestic) violence at any time during the reporting period.	Process	Social Issues	Violence
88		IPF Alcohol Use Screening completed within one day of admission	Alcohol Use Screening completed within one day of patient's admission to the IPF. This is a companion measure to MUC XDFGC -- IPF Drug Use Screening completed within one day of admission.	Process	ODU Treatment	ODU Screening
89		IPF Drug Use Screening completed within one day of admission	Drug Use Screening completed within one day of patient's admission to the IPF. This is a companion measure to MUC XDFGD -- IPF Alcohol Use Screening completed within one day of admission.	Process	ODU Treatment	ODU Screening
90		IPF Suicide Risk Screening completed within one day of admission	Percentage of admissions to an IPF for which a detailed screening for risk of suicide was completed within one day of admission.	Process	ODU Treatment	Psychiatric and/or Other Illness Comorbidity
91		IPF Violence Risk Screening completed within one day of admission	Percentage of admissions for which a detailed screening for risk of violent behavior was completed within one day of admission.	Process	Social Issues	Violence
92		Kidney Stones: Opioid utilization after ureteroscopy	Percentage of patients who underwent ureteroscopy and are discharged on NSAIDs, Acetaminophen, or "Other" and who were not prescribed opioids for pain control	Process	Pain Management	Non-Opioid Pain Management
93	Endorsed	MDS 3.0 Measure (#0676): Percent of Residents Who Self-Report Moderate to Severe Pain (Short Stay)	This measure captures the percent of short stay residents, with at least one episode of moderate/severe pain or horrible/excruciating pain of any frequency, in the last 5 days.	Outcome	Pain Management	Pain Assessment
94	Endorsed	MDS 3.0 Measure (#0677): Percent of Residents Who Self-Report Moderate to Severe Pain (Long Stay)	This measure captures the percent of long-stay residents who report either (1) almost constant or frequent moderate to severe pain in the last 5 days or (2) any very severe/horrible in the last 5 days.	Outcome	Pain Management	Pain Assessment

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
95		Median Time to Pain Management for Long Bone Fracture	Median time from emergency department arrival to time of initial oral or parenteral pain medication administration for emergency department patients with a principal diagnosis of long bone fracture (LBF).	Process	Pain Management	Time to Pain Management
96		Medication Prescribed For Acute Migraine Attack	Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended medication for acute migraine attacks within the 12 month measurement period.	Process	Pain Management	Non-Opioid Pain Management
97		Medication Reconciliation at Admission	This measure assesses the percentage of inpatient psychiatric facility (IPF) hospitalizations with medication reconciliation completed within 24 hours of admission. The performance period for the measure is one year.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
98	Endorsed	Medication Reconciliation Post-Discharge	The percentage of discharges from any inpatient facility (e.g. hospital, skilled nursing facility, or rehabilitation facility) for patients 18 years and older of age seen within 30 days following discharge in the office by the physician, prescribing practitioner, registered nurse, or clinical pharmacist providing on-going care for whom the discharge medication list was reconciled with the current medication list in the outpatient medical record.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
99		Mental Health Response at Twelve Months - Progress Toward Recovery	Patients age 18 and older with an initial score equivalent to ten or higher on the Patient Health Questionnaire (PHQ-9) OR equivalent to ten or higher on the Generalized Anxiety Disorder 7-Item (GAD-7), who demonstrate progress toward social goals at twelve months (+/- 60 days after an index visit) defined as an increase in score equivalent to 4 or higher on the PROMIS Satisfaction with Social Roles and Activities.	Outcome: PRO-PM	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
100		Multimodal Pain Management	Percentage of patients, regardless of age, undergoing selected elective surgical procedures that were managed with multimodal pain medicine.	Process	Pain Management	Non-Opioid Pain Management
101		Narcotic Pain Medicine Management Following Elective Spine Procedure	Percentage of patients aged 18 years and older with documentation of narcotic use/requirements at baseline (initial encounter) and at 3 months following initial assessment and interventions for treatment of spine-related pain symptoms and documentation of follow-up plan.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
102		No or Reduced Criminal Justice Involvement	The percentage of Community Mental Health (CMH) assessed members with no or reduced criminal justice involvement	Outcome	Social Issues	Criminal Justice
103	Endorsed	Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)	Percentage of patients, regardless of age, with a diagnosis of cancer who are currently receiving chemotherapy or radiation therapy that have moderate or severe pain in the first two visits and for which there is a documented plan of care to address pain.	Process	Pain Management	Pain Care Plan
104	Endorsed	Oncology: Medical and Radiation - Plan of Care for Moderate to Severe Pain	Percentage of patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having moderate to severe pain with a plan of care to address pain documented on or before the date of the second visit with a clinician	Process	Pain Management	Pain Care Plan
105	Endorsed	Oncology: Medical and Radiation Pain Intensity Quantified (eQIM)	Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified	Process	Pain Management	Pain Assessment

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
106		Opioid Monitoring	The purpose of this measure is to improve the monitoring, based on evidence-based guidelines, of IPF patients prescribed opioids for increased risk of opioid use disorder (OUD) and substance use by conducting urine drug testing (UDT) and prescription drug monitoring program (PDMP) review.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
107		Opioid Screening	The purpose of this measure is to improve the universal screening of patients admitted to the IPF to identify opioid use by conducting a urine drug screen (UDS) and prescription drug monitoring program (PDMP) review.	Process	OUD Treatment	OUD Screening
108		Opioid Therapy Follow-up Evaluation	All patients 18 and older prescribed opiates for longer than 6 weeks duration who had a follow-up evaluation conducted at least every 3 months during Opioid Therapy documented in the medical record	Process	OUD Treatment	OUD Treatment Continuity
109		Opioid-Related Symptom Distress Scale	The Opioid-Related Symptom Distress Scale (ORSDS) is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 symptoms.	Outcome	Pain Management	Appropriate Opioid Analgesic Prescribing
110		Opioids: Hospital-level risk-standardized medication side effect rate following THA and/or TKA (Opioid-induced respiratory depression)	This measure estimates a risk-standardized opioid-related respiratory depression rate associated with elective primary total hip arthroplasty (THA) and/or total knee arthroplasty (TKA). The outcome is defined as any incidence of opioid-induced respiratory depression occurring from the date of index admission to discharge from the hospital. The target population is patients who are 65 years and older, are enrolled in fee-for-service (FFS) Medicare, and hospitalized in nonfederal acute-care hospitals.	Outcome	Harm Reduction	Overdose
111		Osteoarthritis (OA): Function and Pain Assessment	Percentage of patient visits for patients aged 21 years and older with a diagnosis of osteoarthritis (OA) with assessment for function and pain	Process	Pain Management	QoL/Function
112		Outcome of High Risk Pain Medications Prescribed in Last 6 Months	Percentage of patients aged 18 years and older prescribed and actively taking one or more high risk medications in the last 6 months meeting the following criteria: o Evaluation of polypharmacy AND o Reduction to the high risk medication where clinically appropriate (e.g., change pain medication, number of medications, dosage and/or frequency prescribed)	Outcome	Pain Management	Appropriate Opioid Analgesic Prescribing
113		Overuse of barbiturate and opioid containing medications for primary headache disorders	Percentage of patients age 12 years and older with a diagnosis of primary headache who were prescribed opioid or barbiturate containing medications assessed for medication overuse headache within the 12-month measurement period, and if identified as overusing opioid or barbiturate containing medication, treated or referred for treatment.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
114		Overuse Of Opioid Containing Medications For Primary Headache Disorders	Percentage of patients aged 12 years and older diagnosed with primary headache disorder and taking opioid containing medication who were assessed for opioid containing medication overuse within the 12-month measurement period and treated or referred for treatment if identified as overusing opioid containing medication.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
115	Endorsed	Pain Assessment	The percentage of hospice patients who screened positive for pain and who received a comprehensive assessment of pain within 1 day of screening.	Process	Pain Management	Pain Assessment

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
116		Pain Assessment and Follow-Up	Percentage of patients aged 18 years and older with documentation of a pain assessment through discussion with the patient including the use of a standardized tool(s) on each visit AND documentation of a follow-up plan when pain is present.	Process	Pain Management	Pain Assessment
117		Pain Assessment and Follow-Up for Patients with Dementia	Percentage of patients with dementia who underwent documented screening * for pain symptoms at every visit and if screening was positive also had documentation of a follow-up plan.	Process	Pain Management	Pain Assessment
118		Pain Assessment and Follow-up Reporting Measure	Facility reports in CROWNWeb one of the six conditions below for each qualifying patient once before August 1, 2017 and once before February 1, 2018. Based on NQF #0420. 1. Facilities must report one of the following conditions for each eligible patient: a) Pain assessment using a standardized tool is documented as positive and a follow-up plan is documented b) Pain assessment documented as positive, a follow-up plan is not documented, and the facility possesses documentation that the patient is not eligible c) Pain assessment documented as positive using a standardized tool, a follow-up plan is not documented, and no reason is given d) Pain assessment using a standardized tool is documented as negative, and no follow-up plan required e) No documentation of pain assessment, and the facility possesses documentation the patient is not eligible for a pain assessment using a standardized tool f) No documentation of pain assessment, and no reason is given 2. Conditions covering the first six months of the performance period must be reported in CROWNWeb before August 1, 2017, and the conditions covering the second six months of the performance period must be reported in CROWNWeb before February 1, 2018.	Process	Pain Management	Pain Assessment
119	x	Pain Assessment Conducted	Percentage of home health episodes of care in which the patient was assessed for pain, using a standardized pain assessment tool, at start/resumption of care.	Process	Pain Management	Pain Assessment
120		Pain Assessments and Target Setting for Patients with Osteoarthritis	Percentage of patients 18 years of age and older with a diagnosis of osteoarthritis (OA) for whom a score from one of a select list of validated pain interference or global health assessment tools was recorded at least twice during the measurement period and for whom a target was documented and linked to the initial assessment.	Process	Pain Management	Pain Care Plan
121	Endorsed	Pain Brought Under Control Within 48 Hours	Patients aged 18 and older who report being uncomfortable because of pain at the initial assessment (after admission to palliative care services) who report pain was brought to a comfortable level within 48 hours	Outcome	Pain Management	Time to Pain Management
122		Pain Brought Under Control within the first three visits	Percent of patients 18 and older who report being uncomfortable because of pain at the initial palliative care assessment who report pain was brought to a comfortable level (e.g. "Comfortable? Yes/No", "mild" or pain score < 4) within the first three visits	Outcome	Pain Management	Time to Pain Management
123		Pain Interference Response utilizing PROMIS	The percentage of adult patients (18 years of age or older) who report pain issues and demonstrated a response to treatment at one month from the index score	Outcome: PRO-PM	Pain Management	Pain Score Change

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
124		Pain Interventions Implemented during All Episodes of Care	Percentage of all home health episodes of care during which pain interventions were included in the physician-ordered plan of care and implemented (since the previous OASIS assessment).	Process	Pain Management	Pain Care Plan
125		Pain Interventions Implemented During Long Term Episodes Of Care	Percentage of long term home health episodes of care during which pain interventions were included in the physician-ordered plan of care and implemented (since the previous OASIS assessment).	Process	Pain Management	Pain Care Plan
126		Pain Interventions Implemented During Short Term Episodes Of Care	Percentage of short term home health episodes of care during which pain interventions were included in the physician-ordered plan of care and implemented (since the previous OASIS assessment).	Process	Pain Management	Pain Care Plan
127		Pain Interventions In Plan Of Care	Percentage of home health episodes of care in which the physician-ordered plan of care includes intervention(s) to monitor and mitigate pain.	Process	Pain Management	Pain Care Plan
128	Endorsed	Pain Screening	The percentage of hospice patients who were screened for pain during the initial nursing assessment.	Process	Pain Management	Pain Assessment
129		Pain, Function and General Health Postoperative Improvement	<p>Performance Measure #1 - Change in the calculated score of a validated general health, function, and/or pain score using a standard patient reported outcome survey from before to after surgery.</p> <p>Performance Measure #2 - The overall percentage of patients that improve their general health, function, and/or pain scores beyond a minimum threshold for each postoperative interval.</p> <p>Instructions: Patients who undergo a surgical procedure are asked to complete an outcomes survey both preoperatively and following surgery.</p> <p>Rationale: Understanding a patient's mental and general physical improvement, functional improvement, and improvement in pain levels as a result of surgery is an important aspect of clinical care. The general health scores, functional scores, and pain scores that are calculated can be used to improve a specific patient's care plan or can be analyzed retrospectively to modify overall treatment methodologies. Doctors have the option of collecting a postoperative outcomes survey at different intervals following surgery to account for different surgery types and physician follow-up patterns.</p>	Outcome: PRO-PM	Pain Management	Pain Score Change
130		Patient Acceptable Symptom State Outcomes	Percentage of patients 18 years or older who completed a baseline and, within the CY(calendar year) reporting period of Jan. 1, 20xx - Dec.31, 20xx, a follow-up Patient Acceptable Symptoms State (PASS) assessment that showed a statistically significant improvement in comparison to initial assessment or who had already reported a score in which there is no room for statistical improvement. The use of Patient Reported Outcomes (PROs) in clinical research is well documented.	Outcome	Pain Management	Pain Score Change
131		Patient Queried about Pain and Pain Interference with Function	All visits for patients diagnosed with a muscular dystrophy (MD) where the patient was queried about pain and pain interference with function using a validated and reliable instrument*.	Process	Pain Management	QoL/Function
132		Patient Reported Pain in Cancer Following Chemotherapy	The PRO-PM will assess clinically meaningful change in pain following completion of chemotherapy administered with curative intent to adult patients with breast cancer, colon cancer, and non-small cell lung cancer (NSCLC).	Outcome: PRO-PM	Pain Management	Pain Score Change

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
133		Patient Satisfaction With Spine Care	Percentage of patients aged 18 years and older undergoing spine intervention(s) who completed 3-month follow-up (patient-reported) satisfaction with care assessment. Satisfaction will be reported as % of patients reporting satisfaction with procedure. This measure will be calculated with 2 performance rates: 1) Rate 1: Patient population with Follow-up/Patient population with baseline 2) Rate 2: Patient population with improvement in satisfaction with care status after Follow-up/Patient population with Follow-up. Overall Rate = Rate 2	Outcome	Pain Management	Pain Score Change
134		Patient-Reported Experience with Anesthesia	Percentage of patients, aged 18 and older, who were surveyed on their patient experience and satisfaction with anesthesia care and who reported a positive experience. This measure will consist of two performance rates: AQI48a: Percentage of patients, aged 18 and older, who were surveyed on their patient experience and satisfaction with anesthesia care AQI48b: Percentage of patients, aged 18 and older, who completed a survey on their patient experience and satisfaction with anesthesia care who report a positive experience with anesthesia care NOTE: The measure requires that a valid survey, as defined in the numerator, be sent to patients between discharge from the facility and within 30 days of facility discharge. To report AQI 48b, a minimum number of 20 surveys with the mandatory question completed must be reported.	Outcome: PRO-PM	Pain Management	Pain Assessment
135		Patient-Reported Pain and/or Function Improvement after ACLR Surgery	Percentage of patients 13 years of age and older who obtained at least a 10% improvement in knee pain and/or function as measured by validated patient-reported outcome measures (PROMs) completed up to 90 days prior to and 9 to 15 months after undergoing primary anterior cruciate ligament reconstruction (ALCR) surgery. PROMs include any validated measures of knee-related measures of pain and/or function, such as KOOS-Pain, KOOS-ADL, KOOS-PS, and KOOS-JR.	Outcome: PRO-PM	Pain Management	QoL/Function
136		Patient-Reported Pain and/or Function Improvement after APM Surgery	Percentage of patients 13 years of age and older who obtained at least a 10% improvement in knee pain and/or function as measured by validated patient-reported outcome measures (PROMs) completed up to 90 days prior to and 9 to 15 months after undergoing primary arthroscopic partial meniscectomy (APM) surgery. PROMs include any validated measures of knee-related pain and/or function, such as KOOS-Pain, KOOS-ADL, KOOS-PS, and KOOS-JR.	Outcome: PRO-PM	Pain Management	QoL/Function
137		Patient-Reported Pain and/or Function Improvement after Total Hip Arthroplasty	Percentage of patients 18 years of age and older who obtained at least a 10% improvement in hip pain and/or function as measured by validated patient-reported outcome measures (PROMs) completed up to 90 days prior to and 9 to 15 months after undergoing primary total hip arthroplasty (THA) surgery. PROMs include any validated measures of hip-related pain and/or function, such as HOOS-Pain, HOOS-ADL, HOOS-PS, and HOOS-JR.	Outcome: PRO-PM	Pain Management	QoL/Function

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
138		Patient-Reported Pain and/or Function Improvement after Total Knee Arthroplasty	Percentage of patients 18 years of age and older who obtained at least a 10% improvement in knee pain and/or function as measured by validated patient-reported outcome measures (PROMs) completed up to 90 days prior to and 9 to 15 months after undergoing primary total knee arthroplasty (TKA) surgery. PROMs include any validated measures of knee-related measures of pain and/or function, such as KOOS-Pain, KOOS-ADL, KOOS-PS, and KOOS-JR.	Outcome: PRO-PM	Pain Management	QoL/Function
139		Patient-Reported Pain and/or Function Improvement after Total Shoulder Arthroplasty	Percentage of patients 18 years of age and older who obtained at least a 10% improvement in shoulder pain and/or function as measured by validated patient-reported outcome measures (PROMs) completed up to 90 days prior to and 9 to 15 months after undergoing primary total shoulder arthroplasty (TSA) surgery. PROMs include any validated measures of shoulder-related pain and/or function, such as PSS-Pain and PSS-Function.	Outcome: PRO-PM	Pain Management	QoL/Function
140	Endorsed	Patients Treated with an Opioid who are Given a Bowel Regimen	Percentage of vulnerable adults treated with an opioid that are offered/prescribed a bowel regimen or documentation of why this was not needed	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
141		Percent days abstinent from alcohol	This measure was developed by staff of the Butler Center for Research (BCR), the research and clinical data analytic arm of the Hazelden Betty Ford Foundation, a national nonprofit alcohol/drug treatment provider. The BCR has been and is currently responsible for collection, analysis and reporting of post-treatment outcomes data for patients attending HBFF treatment programs. This outcomes measurement and reporting takes place on a rolling basis as part of routine healthcare operations. The BCR has designed our own outcomes surveys, which are administered by phone by BCR callers roughly 1, 6 and 12 months after patients discharge. Many of the questions on these surveys ask patients to self-report on substance use since leaving treatment. One of these questions asks patients to indicate the total number of days since treatment that they have drank at least 1 drink containing alcohol. The answer to this question is used to determine PDA from alcohol: among individuals who have recently attended alcohol addiction treatment at a HBFF program, the average percentage of days since treatment discharge that they have abstained from drinking alcohol. The measure we submit here pertains to the 6 month follow up survey; administered roughly 6 months after discharge. Hence, the measure is percent days abstinent (PDA) from alcohol at 6 months post-treatment (the mean or average for the sample of patients).	Outcome: PRO-PM	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
142		Percent of Chronic Opioid Analgesic Therapy Enrollees Receiving Opioids from Multiple Providers	The percent of patients receiving chronic opioid analgesic therapy (COAT) from a chronic opioid prescriber who received opioid prescriptions from 2 or more additional prescribers during the time span in which they received COAT.	Process	OUD Treatment	OUD Screening
143		Percent of Medicaid beneficiaries receiving buprenorphine who have a documented diagnosis of opioid use disorder (OUD).	The purpose of this measure is to assess the percentage of Medicaid beneficiaries receiving buprenorphine (alone or in combination with naloxone) who have a DSM-5 diagnosis of opioid use disorder.	Process	OUD Treatment	OUD Treatment Initiation

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
144		Percent of patients meeting SCB thresholds for back or neck pain	Calculation of the percent of patients who meet the substantial clinical benefit (SCB) thresholds for improvement in back or neck pain following a spine surgical intervention (cervical or lumbar)	Outcome	Pain Management	Pain Score Change
145		Percent of patients meeting SCB thresholds for leg or arm pain	Calculation of the percent of patients who meet the substantial clinical benefit (SCB) thresholds for improvement in leg or arm pain following a spine surgical intervention (cervical or lumbar)	Outcome	Pain Management	Pain Score Change
146		Percent of patients meeting SCB thresholds for pain-related disability (ODI/NDI)	Calculation of the percent of patients who meet the substantial clinical benefit (SCB) thresholds for improvement in pain-related disability following a spine surgical intervention (cervical or lumbar)	Outcome	Pain Management	Pain Score Change
147		Percent of patients prescribed a medication for alcohol use disorder (AUD)	This measure will be used to assess the extent to which clinicians prescribe medications to treat AUD to their patients.	Process	ODU Treatment	Psychiatric and/or Other Illness Comorbidity
148		Percent of patients prescribed a medication for opioid use disorder (OUD)	This measure will be used to assess the extent to which clinicians make medications available to their patients with an OUD.	Process	ODU Treatment	ODU Treatment Initiation
149		Percent of Patients with Chronic Opioid Analgesic Therapy	The percent of patients receiving chronic opioid analgesic therapy (COAT) prescribed at least one opioid by the health care provider.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
150	Endorsed	Percent of Residents Who Self-Report Moderate to Severe Pain (Short Stay)	This measure reports the percentage of short-stay residents or patients with a 14-day PPS assessment during a selected quarter (3 months) who have reported almost constant or frequent pain and at least one episode of moderate to severe pain, or any severe or horrible pain, in the 5 days prior to the 14-day PPS assessment.	Outcome	Pain Management	Pain Assessment
151		Percent of Skilled Nursing Facility Residents Who Self-Report Moderate to Severe Pain	This measure reports the percentage of skilled nursing facility residents who have reported daily pain with at least one episode of moderate to severe pain, or severe or horrible pain of any frequency in the 5 days prior to the assessment.	Outcome	Pain Management	Pain Assessment
152		Perioperative Pain Plan	Percentage of patients with signed documentation that a perioperative pain plan using a multimodal, narcotic sparing technique was discussed	Process	Pain Management	Pain Care Plan
153		Pharmacologic Management of Migraine Headaches	Percent of members ages 19-65 diagnosed with migraine who received first-line migraine specific therapy prior to receiving opiate or butalbital containing rescue medications.	Process	Pain Management	Non-Opioid Pain Management
154		Plan Of Care Or Referral For Possible Medication Overuse Headache	Percentage of patients diagnosed with medication overuse headache (MOH) within the past 3 months or who screened positive for possible MOH (measure 6a) who had a medication overuse plan of care created or who were referred for this purpose.	Process	Pain Management	Pain Care Plan
155		Post-operative opioid management following oculoplastic surgery	Percentage of patients aged 18 years and older who underwent oculoplastic surgical procedures who were assessed for opioid use/requirements post-operatively, defined by either not receiving opioids post-operatively, receiving opioids for pain for 7 days or less post-operatively, or if expected to require opioids for more than 7 days after the surgical procedure, having an opioid use management plan documented.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
156		Potential Opioid Overuse	Percentage of patients aged 18 years or older who receive opioid therapy for 90 days or longer and are prescribed a 90 milligram or larger morphine equivalent daily dose	Process	ODU Treatment	ODU Screening

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
157		Pregnancy test in women with a suspected toxicologic exposure	Percentage of women of childbearing age (12-60 years) who are seen by a medical toxicologist in the emergency department or inpatient setting with a suspected toxicologic exposure, who receive a pregnancy test prior to emergency department discharge or within 24 hours of hospital admission.	Process	OUD Treatment	OUD Screening
158		Preoperative Assessment for Opioid Dependence Risk	Percentage of patients, aged 18 years and older, who undergo preoperative assessment of opioid dependence risk prior to elective surgery and care team is notified.	Process	OUD Treatment	OUD Screening
159		Preoperative Screening for Anesthetic Risk Factors	Percentage of patients, regardless of age, undergoing a surgical, therapeutic or diagnostic procedures under anesthesia in an operating/procedure room during the performance period and who have a documented use of a pre-operative assessment of two or more anesthetic risk factors prior to the start of anesthesia and the procedure did not result in an impairment of anesthesia or the patient did not experience a decrease in the effectiveness of anesthesia. Risk factor assessment must include at least two of the following: <ul style="list-style-type: none"> • Symptoms of Gastroesophageal Reflux Disease • History of Glaucoma or elevated eye pressures • Post-operative Nausea and Vomiting risk factors • Alcohol and recreational drug use • Herbal supplements and antibiotic impairment of anesthesia 	Process	OUD Treatment	OUD Screening
160		Prescribing Rate of 700 Cumulative MME or Greater During an Initial Opioid Prescribing Episode	The percentage of opioid prescriptions prescribed during the initial index opioid prescribing episode which expose a patient to 700 cumulative Morphine Milligram Equivalence (MME) or more. The prescriber of the prescription that meets or exceeds the 700 cumulative MME threshold does not need to be the prescriber of previous prescriptions in the initial opioid prescribing episode.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
161		Prescribing Rate of an Index Opioid Prescription Greater than the Recommended Dose	The percentage of index opioid prescriptions prescribed in the measurement year that exceed the recommended 100 or 200 Morphine Milligram Equivalence (MME) dose limit. · The 100 MME dose limits applies to prescribers identified as a primary care or non-surgical medical specialists. · The 200 MME dose limit applies to prescribers identified as surgical specialists, including Obstetricians and Gynecologists.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
162		Presence of screening for psychiatric disorder	This measure assesses the extent to which patients with an SUD diagnosis, receiving addiction treatment, are formally assessed for a psychiatric diagnosis.	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
163		Presence of screening for tobacco use disorder	This measure assesses the extent to which patients with an SUD diagnosis, receiving addiction treatment, are screened for a tobacco use disorder diagnosis.	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
164		Pre-surgical screening for depression	Percentage of patients, regardless of age, undergoing surgical, therapeutic or diagnostic procedures under anesthesia where the patient a received a formal pre-surgical screening for depression using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
165		Preventative Care and Screening: Tobacco Screening and Cessation Intervention	Percentage of patients age 18 or older who are active tobacco users who receive tobacco screening AND are offered cessation counseling at least 2 months prior to elective surgical procedure in order to delay the procedure until smoking cessation is possibly achieved.	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
166	Endorsed	Preventive Care and Screening: Screening for Depression and Follow-Up Plan (eCQM)	Percentage of patients aged 12 years and older screened for depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
167	Endorsed	Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling	Percentage of patients aged 18 years and older who were screened for unhealthy alcohol use using a systematic screening method at least once within the last 24 months AND who received brief counseling if identified as an unhealthy alcohol user	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
168		Primary care visit follow-up	This measure identifies the proportion of individuals who have a primary care visit after an SUD treatment encounter, and assesses the extent to which clinicians assure comprehensive patient care.	Process	OUD Treatment	OUD Treatment Continuity
169		Psychiatric disorder diagnosis presence	This measure will assess the extent to which patients with an SUD diagnosis, receiving addiction treatment, have a documented psychiatric diagnosis or an explicit entry of "no mental disorder diagnosis" or "mental disorder diagnosis deferred."	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
170		Quality Of Life Assessment For Patients With Primary Headache Disorders	Percentage of patients with a diagnosis of primary headache disorder whose health related quality of life (HRQoL) was assessed with a tool(s) during at least two visits during the 12 month measurement period AND whose health related quality of life score stayed the same or improved	Outcome: PRO-PM	Pain Management	QoL/Function
171		Quality of Life for Patients with Neurotology Disorders	Percentage of neurotology patients whose most recent Quality of Life scores were maintained or improved during the measurement period.	Outcome: PRO-PM	Pain Management	QoL/Function
172		Quality of Life-Mental Health Outcomes	Percentage of patients 18 years of age and older who completed a baseline and, within the CY(calendar year) reporting period of Jan. 1, 20xx - Dec.31, 20xx, follow-up quality of life (QoL) patient-reported outcomes assessment (VR-12, SF-12, SF-36, PROMIS Global 10 or equivalent Computer Adaptive Test (CAT) assessment if available) which yielded a mental component score that showed a statistically significant improvement in comparison to initial assessment or who had already reported a score in which there is no room for statistical improvement. The use of Patient Reported Outcomes (PROs) in clinical research is well documented. In addition, the AAOS Quality Outcomes Work Group recommends that QoL PROs in the clinical setting can lead to improved care.	Outcome: PRO-PM	OUD Treatment	Psychiatric and/or Other Illness Comorbidity

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
173		Quality-of-Life Assessment for Spine Intervention	Percentage of patients aged 18 years and older undergoing index spine intervention(s) who completed baseline and 3-month follow-up (patient-reported) quality-of-life assessment, with an improvement in the quality of life status from baseline. This measure will be calculated with 2 performance rates: 1) Rate 1: Patient population with Follow-up/Patient population with baseline 2) Rate 2: Patient population with improvement in quality of life status after Follow-up/Patient population with Follow-up. Overall Rate = Rate 2	Outcome: PRO-PM	Pain Management	QoL/Function
174		Query of Prescription Drug Monitoring Program (PDMP)	For at least one Schedule II opioid electronically prescribed using CEHRT during the performance period, the MIPS eligible clinician uses data from CEHRT to conduct a query of a PDMP for prescription drug history, except where prohibited and in accordance with applicable law.	Process	OUD Treatment	OUD Screening
175		Querying about Pain and Pain Interference with Function	Percentage of patient visits for patient age 18 years and older with a diagnosis of distal symmetric polyneuropathy who was queried about pain and pain interference with function using a valid and reliable instrument.	Process	Pain Management	QoL/Function
176		Reduction in Patient Reported Pain Following Medial Branch Radiofrequency Ablation	Measurement of reduction in pain as reported by patients aged 18 years and older following medial branch radiofrequency ablation	Outcome: PRO-PM	Pain Management	Pain Score Change
177		Risky Behavior Assessment or Counseling by Age 13 Years	The percentage of children with documentation of a risk assessment or counseling for risky behaviors by 13 years of age. Four rates are reported: Risk Assessment or Counseling for Alcohol Use, Risk Assessment or Counseling for Tobacco Use, Risk Assessment or Counseling for Other Substance Use, Risk Assessment or Counseling for Sexual Activity.	Process	OUD Treatment	OUD Screening
178		Risky Behavior Assessment or Counseling by Age 18 Years	The percentage of children with documentation of a risk assessment or counseling for risky behaviors by 18 years of age. Four rates are reported: Risk Assessment or Counseling for Alcohol Use, Risk Assessment or Counseling for Tobacco Use, Risk Assessment or Counseling for Other Substance Use, Risk Assessment or Counseling for Sexual Activity.	Process	OUD Treatment	OUD Screening
179		Safe Opioid Prescribing Practices	Percentage of patients, aged 18 years and older, prescribed opioid medications for longer than six weeks' duration for whom ALL of the following opioid prescribing best practices are followed: 1. Chemical dependency screening (includes laboratory testing and/or questionnaire) within the immediate 6 months prior to the encounter 2. Co-prescription of naloxone or documented discussion regarding offer of Naloxone co-prescription, if prescription is ≥50 MME/day 3. Non co-prescription of benzodiazepine medications by prescribing pain physician and documentation of a discussion with patient regarding risks of concomitant use of benzodiazepine and opioid medications.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
180	Endorsed	Safe Use of Opioids – Concurrent Prescribing	Patients age 18 years and older prescribed two or more opioids or an opioid and benzodiazepine concurrently at discharge from a hospital-based encounter (inpatient or emergency department [ED], including observation stays)	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
181		Safe Use of Opioids at Time of Care Transitions	Proportion of patients ages 18 years and older who are treated in a hospital care setting who depart with a new opioid prescription not present on arrival and whose level of risk for opioid-related adverse drug events (ADEs) has been assessed and documented. NOTE: This is the draft description of the measure. The final description is dependent on questions we will consider through development and with the expert workgroup (EWG). See Stratification, Risk Adjustment, Clinical Recommendation Statement, Definition, Initial Population, and Denominator Exclusions.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
182		Screening and monitoring for psychosocial problems among children and youth	Percentage of children from 3.00 to 17.99 years of age who are administered a parent-report, standardized and validated screening tool to assess broad-band psychosocial problems during an intake visit AND who demonstrated a reliable change in parent-reported problem behaviors 2 to 6 months after initial positive screen for externalizing and internalizing behavior problems.	Outcome: PRO-PM	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
183		Screening for Clinical Depression	Percentage of patients aged 18 years and older screened for clinical depression using a standardized tool and follow-up plan documented.	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
184		Screening for risk of opioid misuse/overuse	Percentage of patients aged 12 years or older who were screened for the potential risk of opioid misuse/overuse	Process	OUD Treatment	OUD Screening
185		Spine/Extremity Pain Assessment	Percentage of patients aged 18 years and older with documentation of a pain assessment through discussion with the patient including the use of a standardized back or neck pain tool(s) AND/OR leg or arm pain tool(s) at baseline and 3 months following initial assessment and intervention(s) for treatment of spine-related pain symptoms with at least 10% improvement in the pain status from the baseline and documentation of follow-up plan. This measure will be calculated with 2 performance rates: 1) Rate 1: Patient population with Follow-up/Patient population with baseline 2) Rate 2: Patient population with improvement in pain status after Follow-up/Patient population with Follow-up. Overall Rate = Rate 2	Outcome	Pain Management	Pain Assessment
186		Stabilization in Anxiety Level	Percentage of home health episodes of care during which the patient's anxiety became less frequent or stayed the same as at admission.	Outcome	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
187		Standardized functional assessment	Percentage of individuals who have documentation of assessment of function (physical, mental, and social functioning) using a standardized assessment instrument at two points in time.	Process	OUD Treatment	OUD Screening

#	NQF-Endorsed ?	Measure Title	Description	Measure Type	Domain	Subdomain
188		SUB-2 Alcohol Use Brief Intervention Provided or Offered and SUB-2a Alcohol Use Brief Intervention	The measure is reported as an overall rate which includes all hospitalized patients 18 years of age and older to whom a brief intervention was provided, or offered and refused, and a second rate, a subset of the first, which includes only those patients who received a brief intervention. The Provided or Offered rate (SUB-2), describes patients who screened positive for unhealthy alcohol use who received or refused a brief intervention during the hospital stay. The Alcohol Use Brief Intervention (SUB-2a) rate describes only those who received the brief intervention during the hospital stay. Those who refused are not included.	Process	ODU Treatment	Psychiatric and/or Other Illness Comorbidity
189		SUB-3 Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and SUB-3a Alcohol & Other Drug Use Disorder Treatment at Discharge	The measure is reported as an overall rate which includes all hospitalized patients 18 years of age and older to whom alcohol or drug use disorder treatment was provided, or offered and refused, at the time of hospital discharge, and a second rate, a subset of the first, which includes only those patients who received alcohol or drug use disorder treatment at discharge. The Provided or Offered rate (SUB-3) describes patients who are identified with alcohol or drug use disorder who receive or refuse at discharge a prescription for FDA-approved medications for alcohol or drug use disorder, OR who receive or refuse a referral for addictions treatment. The Alcohol and Other Drug Disorder Treatment at Discharge (SUB-3a) rate describes only those who receive a prescription for FDA-approved medications for alcohol or drug use disorder OR a referral for addictions treatment. Those who refused are not included.	Process	ODU Treatment	ODU Treatment Initiation
190		SUB-4 Alcohol & Drug Use: Assessing Status After Discharge	Hospitalized patients age 18 years and older who screened positive for unhealthy alcohol use or who received a diagnosis of alcohol or drug disorder during their inpatient stay, who are contacted between 7 and 30 days after hospital discharge and follow-up information regarding their alcohol or drug use status post discharge is collected. This measure is intended to be used as part of a set of 4 linked measures addressing Substance Use (SUB-1) Alcohol Use Screening; SUB-2 Alcohol Use Brief Intervention Provided or Offered; SUB-3 Alcohol and Other Drug Use Disorder Treatment Provided or Offered at Discharge; SUB-4 Alcohol and Drug Use: Assessing Status after Discharge).	Process	ODU Treatment	ODU Treatment Continuity
191		Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counseled regarding psychosocial AND pharmacologic treatment options for opioid addiction within the 12 month reporting period	This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counseled regarding psychosocial and pharmacologic treatment options for opioid addiction within the 12 month reporting period.	Process	ODU Treatment	ODU Treatment Initiation
192		Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	Percentage of patients aged 18 years and older with a diagnosis of current substance abuse or dependence who were screened for depression within the 12-month reporting period	Process	ODU Treatment	Psychiatric and/or Other Illness Comorbidity

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
193	endorsed	Substance Use Screening and Intervention Composite	Percentage of patients aged 18 years and older who were screened at least once within the last 24 months for tobacco use, unhealthy alcohol use, nonmedical prescription drug use, and illicit drug use AND who received an intervention for all positive screening results	Composite	OUD Treatment	OUD Treatment Initiation
194		SUD diagnosis documentation in addiction treatment	This measure will assess the extent to which clinicians document an SUD diagnosis for the patients they are treating, regardless of treatment setting.	Process	OUD Treatment	OUD Treatment Continuity
195		Surgical Phases of Care Patient-Reported Outcome Composite Measure	Composite measure consisting of 12 items intended to measure the constructs of Surgeon Communication Before Surgery, Surgical Goals of Care, Satisfaction with Information, and Postoperative Care Coordination from the patient's perspective. Of these 12 items, 9 originate from the CAHPS Surgical Care Survey (S-CAHPS). Specifically, these 9 items are questions 3, 9, 11, 17, 26, 27, 31, 33, and 34 from the original S-CAHPS survey. Three (3) additional items are included to appropriately measure Goals of Care; these questions ask whether the surgeon discussed what the patient hoped to gain from surgery, whether the surgeon discussed how surgery would affect their daily activities, and what life might look like for the patient in the long-term. Please see the attachment for all 12 items in full.	Outcome: PRO-PM	Pain Management	Pain Care Plan
196		Time from first face-to-face treatment encounter to buprenorphine dosing	Number of hours opioid dependent, non-pregnant adults aged 18 or older have to wait between their first face-to-face treatment encounter and receiving their first dose of buprenorphine medication (i.e. medication induction).	Process	OUD Treatment	OUD Treatment Initiation
197	Endorsed	Use of High-Risk Medications in the Elderly	Percentage of patients 65 years of age and older who were ordered high-risk medications. Two rates are submitted. 1) Percentage of patients who were ordered at least one high-risk medication. 2) Percentage of patients who were ordered at least two of the same high-risk medication	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
198		Use of Neuraxial Techniques and/or Peripheral Nerve Blocks for Total Knee Arthroplasty (TKA)	Percentage of patients, regardless of age, that undergo primary total knee arthroplasty for whom neuraxial anesthesia and/or a peripheral nerve block is performed	Process	Pain Management	Non-Opioid Pain Management
199	Endorsed	Use of Opioids at High Dosage in Persons Without Cancer	The proportion (XX out of 1,000) of individuals without cancer receiving prescriptions for opioids with a daily dosage greater than 120mg morphine equivalent dose (MED) for 90 consecutive days or longer.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
200		Use of Opioids at High Dosage in Persons Without Cancer Following Elective Primary THA and/or TKA	This measure estimates the proportion of individuals without cancer receiving prescriptions for opioids with a daily dosage greater than 120mg morphine equivalent dose (MED) for 90 consecutive days or longer following elective primary total hip arthroplasty (THA) and/or total knee arthroplasty (TKA). The target population is patients who are 65 years and older, are enrolled in fee-for-service (FFS) Medicare, and hospitalized in Partners HealthCare (PHS) hospitals.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
201	Endorsed	Use of Opioids from Multiple Providers and at High Dosage in Persons Without Cancer	The rate (XX of 1,000) of individuals without cancer receiving prescriptions for opioids with a daily dosage greater than 120 mg morphine equivalent dose (MED) for 90 consecutive days or longer, AND who received opioid prescriptions from four (4) or more prescribers AND four (4) or more pharmacies.	Process	OUD Treatment	OUD Screening

#	NQF-Endorsed?	Measure Title	Description	Measure Type	Domain	Subdomain
202	Endorsed	Use of Opioids from Multiple Providers in Persons Without Cancer	The rate (XX out of 1,000) of individuals without cancer receiving prescriptions for opioids from four (4) or more prescribers AND four (4) or more pharmacies.	Process	OUD Treatment	OUD Screening
203	Endorsed	Use of pharmacotherapy for opioid use disorder (OUD)	The percentage of Medicaid beneficiaries ages 18 to 64 with an OUD who filled a prescription for or were administered or ordered an FDA-approved medication for the disorder during the measure year. The measure will report any medications used in medication-assisted treatment of opioid dependence and addiction and four separate rates representing the following types of FDA-approved drug products: buprenorphine; oral naltrexone; long-acting, injectable naltrexone; and methadone.	Process	OUD Treatment	OUD Treatment Initiation
204		Ventral Hernia Repair: Pain and Functional Status Assessment	Percentage of patients aged 18 years and older who have undergone ventral hernia repair and who completed baseline and 30 day follow-up patient-reported functional status assessments, and achieved at least a 10% improvement in functional status score from baseline.	Outcome: PRO-PM	Pain Management	QoL/Function
205		Verify Opioid Treatment Agreement	For at least one unique patient for whom a Schedule II opioid was electronically prescribed by the MIPS eligible clinician using CEHRT during the performance period, if the total duration of the patient's Schedule II opioid prescriptions is at least 30 cumulative days within a 6-month look-back period, the MIPS eligible clinician seeks to identify the existence of a signed opioid treatment agreement and incorporates it into the patient's electronic health record using CEHRT.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
206		7-day follow-up after withdrawal management	This measure assesses the extent to which patients initiate treatment within 7 days after receiving withdrawal management services. Because this measure focuses solely on how patients are engaged in addiction treatment post-withdrawal management, this measure will exclude patients engaged in methadone maintenance treatment, patients engaged in office-based opioid treatment that utilizes partial agonist maintenance pharmacotherapy, and patients who enter treatment via intensive outpatient placement with no inpatient/ residential or outpatient withdrawal management services. Thus, a patient who never received withdrawal management services, e.g., because they were not clinically indicated, or because the patient underwent induction onto agonist maintenance pharmacotherapy without undergoing any phase of "withdrawal management," would not be identified via this measure. The purpose of the continuity measure is to assess treatment system contact and engagement beyond the initial follow-up contact within 7 days. Continuity refers to the provision of timely and complementary services within a shared management plan. Disease-specific literature emphasizes the need for care plans to ensure consistency across these treatment locations and providers. Nursing and mental health literature goes further, emphasizing the importance of consistent implementation, especially when patients cross organizational boundaries. However, flexibility in adapting to changes in an individual's needs is equally important, especially in mental health and addiction care.	Process	OUD Treatment	OUD Treatment Initiation

Appendix E: Measure Concept Inventory

#	Measure Description	Measure Type	Domain	Subdomain
1	Average inpatient daily MMEs administered during hospitalization	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
2	Behavioral health integration in medical care instrument	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
3	Clinical Opiate Withdrawal Scale	Process	OUD Treatment	OUD Treatment Continuity
4	Continuity of Pharmacotherapy for Opioid Use	Process	OUD Treatment	OUD Treatment Continuity
5	Current Opioid Misuse Measure is a 17-item survey useful in assessing prescription opioid use in SUD treatment settings	Process	OUD Treatment	OUD Screening
6	Daily MMEs prescribed at discharge	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
7	Days' supply of initial opioid prescription for acute pain.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
8	Discharges from opioid use	Process	OUD Treatment	OUD Treatment Continuity
9	Extended-release opioid prescriptions as a proportion of all initial opioid prescriptions for acute pain.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
10	Extended-release opioid prescriptions as a proportion of all initial opioid prescriptions for chronic pain.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
11	Hospital-level risk standardized opioid extended use following elective THA and/or TKA	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
12	Hospital-level risk standardized opioid respiratory depression following elective THA and/or TKA	Outcome	Harm Reduction	Overdose
13	Improvement or maintenance of functioning for all patients seen for mental health and substance use care	Outcome	OUD Treatment	OUD Treatment Continuity
14	Improvement or maintenance of symptoms for patients with opioid misuse	Outcome	OUD Treatment	OUD Treatment Continuity
15	Initiation of medication assisted treatment among individuals with opioid use disorder	Process	OUD Treatment	OUD Treatment Initiation
16	Integration of HIV and OUD care tool	Process	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
17	Morphine milligram equivalent (MME) of initial opioid prescription for chronic pain.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
18	Neonatal Infant Pain Scale	Process	Pain Management	Pain Assessment
19	Neonatal Pain Agitation and sedation Scale	Process	Pain Management	Pain Assessment
20	Number of opioid prescribers for single patient	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
21	Number of opioid prescriptions per 1,000 office visits	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
22	Number of pills prescribed at discharge	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
23	OD death synthetic opioids	Outcome	Harm Reduction	Overdose
24	Opioid administration among the headache/migraine patients who visited ED	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
25	Opioid burden	Outcome	Social Issues	Opioid Burden
26	Opioid covered-days prescribed to the patients who were discharged from ED	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
27	Overdose deaths any opioid	Outcome	Harm Reduction	Overdose
28	Pain measure for children in inpatient; pain reduction by 30% within 120 minutes of complaint	Outcome: PRO-PM	Pain Management	Time to Pain Management
29	Patient experience of care for all patients seen with mental health and substance use care	Outcome: PRO-PM	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
30	Percentage of hospitalized patients with OUD initiated on medication management	Process	OUD Treatment	OUD Treatment Initiation
31	Percentage of hospitalized patients with OUD on medication management	Process	OUD Treatment	OUD Treatment Initiation
32	Percentage of opioid prescriptions for acute pain with less than 7 day supply	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
33	Percentage of opioid prescriptions with partial fill instructions	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
34	Percentage of opioid-naïve patients prescribed C-II & C-III opioid on emergency department discharge	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
35	Percentage of outpatients with OUD initiated on medication management (buprenorphine/methadone/naltrexone)	Process	OUD Treatment	OUD Treatment Initiation
36	Percentage of patients administered long-acting opioid during hospital stay	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
37	Percentage of patients prescribed buprenorphine among those with opioid disorder diagnoses	Process	OUD Treatment	OUD Treatment Initiation
38	Percentage of Patients Prescribed Chronic Opioid with Risk and Plan Documented	Process	Pain Management	Pain Care Plan
39	Percentage of patients prescribed long-acting opioid at hospital discharge	Process	Pain Management	Appropriate Opioid Analgesic Prescribing

#	Measure Description	Measure Type	Domain	Subdomain
40	Percentage of patients prescribed opioid	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
41	Percentage of patients prescribed opioid at discharge	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
42	Percentage of patients prescribed opioid more than 3 month after surgery	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
43	Percentage of patients prescribed opioid with daily MME > 90 among those who were prescribed	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
44	Percentage of patients signed medication agreement on file among chronic opioid users	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
45	Percentage of patients signed medication agreement on file among patients with long term opioid prescription	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
46	Percentage of patients that received more than 50 MME during at least one day of their hospitalization	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
47	Percentage of patients treated for opioid overdose in emergency department	Process	Harm Reduction	Overdose
48	Percentage of patients with documented Opioid Risk Tool assessment among those on chronic opioids	Process	OUD Treatment	OUD Screening
49	Percentage of patients with Naloxone on medication list while they received opioid with daily MME > 90	Process	Harm Reduction	Opioid Reversal Drug Prescription
50	Percentage of patients with office visits within prior 3 months among chronic opioid users	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
51	Percentage of patients with OUD discharged with naloxone	Process	Harm Reduction	Opioid Reversal Drug Prescription
52	Percentage of patients with OUD receiving treatment	Process	OUD Treatment	OUD Treatment Initiation
53	Percentage of patients with urine drug toxicology among chronic opioid users	Process	OUD Treatment	OUD Screening
54	Percentage of prescribers who have written for 1+ prescription of buprenorphine/nlx	Process	OUD Treatment	OUD Treatment Initiation
55	Percentage of prescribers with a suboxone waiver	Process	OUD Treatment	OUD Treatment Initiation
56	Proportion of patients who received a urine drug test within 30 days before initial opioid prescription (initial screening) and within 365 days after initial opioid prescription (annual screening) for chronic pain.	Process	OUD Treatment	OUD Screening
57	Proportion of patients with a follow-up visit (based on E&M CPT codes) within 30 days after the initial opioid prescription for chronic pain.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
58	Quantity of opioid prescribed to the patients who were discharged from ED	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
59	Rapid Recovery Progression Measure: 6-item	Intermediate Outcome	OUD Treatment	OUD Treatment Continuity
60	Rate of NY Office of Alcoholism and Substance Abuse Services (OUD treatment program) use	Process	OUD Treatment	OUD Treatment Initiation
61	Recovery Progression Measure: 36-item	Intermediate Outcome	OUD Treatment	OUD Treatment Continuity
62	Subjective Opiate Withdrawal Scale	Process	OUD Treatment	OUD Treatment Continuity
63	The percentage of patients on long-term opioid therapy the clinician counseled on the risks and benefits of opioids at least annually.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
64	The percentage of patients on long-term opioid therapy who had a follow-up visit at least quarterly.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
65	The percentage of patients on long-term opioid therapy who had at least quarterly pain and functional assessments.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
66	The percentage of patients on long-term opioid therapy who had documentation that a PDMP was checked at least quarterly.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
67	The percentage of patients on long-term opioid therapy who were counseled on the purpose and use of naloxone, and either prescribed or referred to obtain naloxone	Process	Harm Reduction	Opioid Reversal Drug Prescription
68	The percentage of patients on long-term opioid therapy with documentation that a urine drug test was performed at least annually.	Process	OUD Treatment	OUD Screening
69	The percentage of patients with a follow-up visit within 4 weeks of starting an opioid for chronic pain.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
70	The percentage of patients with a new opioid prescription for acute pain for a three days' supply or less	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
71	The percentage of patients with a new opioid prescription for an immediate-release opioid.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
72	The percentage of patients with a new opioid prescription for chronic pain with documentation that a PDMP was checked prior to prescribing.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing

#	Measure Description	Measure Type	Domain	Subdomain
73	The percentage of patients with a new opioid prescription for chronic pain with documentation that a urine drug test was performed prior to prescribing.	Process	Pain Management	Appropriate Opioid Analgesic Prescribing
74	The percentage of patients with an opioid use disorder (OUD) who were referred to or prescribed medication assisted treatment.	Process	OUD Treatment	OUD Treatment Initiation
75	The percentage of patients with chronic pain who had at least one referral or visit to nonpharmacologic therapy as a treatment for pain.	Process	Pain Management	Non-Opioid Pain Management
76	PROMIS Pain Interference instruments	Outcome: PRO-PM	Pain Management	Pain Assessment
77	PROMIS Physical Function - Short Form	Outcome: PRO-PM	Pain Management	QoL/Function
78	PROMIS Pain Intensity Scale	Outcome: PRO-PM	Pain Management	Pain Assessment
79	PROMIS Emotional Distress-Depression Short Form	Outcome: PRO-PM	OUD Treatment	Psychiatric and/or Other Illness Comorbidity
80	PROMIS Emotional Distress-Anxiety Short Form	Outcome: PRO-PM	OUD Treatment	Psychiatric and/or Other Illness Comorbidity